18F-FNDP for PET imaging of soluble epoxide hydrolase (sEH)

The development of 18F-FNDP as a PET tracer addresses the issue of nonspecific binding in sEH imaging, enabling precise in vivo imaging of sEH distribution and aiding in the differentiation of cerebrovascular diseases.

JP7590726B2Active Publication Date: 2024-11-27JOHNS HOPKINS UNIVERSITY +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2018558208
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-05-04
Filing Date
2017-05-04
Publication Date
2024-11-27
Estimated Expiration
2037-05-04

AI Technical Summary

Technical Problem

Current PET imaging agents for soluble epoxide hydrolase (sEH) lack specificity and viability due to large hydrophobic domains, leading to high nonspecific binding, which hinders accurate molecular imaging of cerebrovascular diseases like Alzheimer's and vascular cognitive impairment.

Method used

Development of N-(3,3-diphenylpropyl)-6-fluoronicotinamide (18F-FNDP), a radioactive tracer with a suitable radioisotope for PET imaging, that selectively labels sEH with high specificity and enters mouse and baboon brains, allowing for precise imaging of sEH distribution.

Benefits of technology

18F-FNDP demonstrates high specificity and stability in vivo, providing clear PET imaging of sEH in animal brains, facilitating the differentiation between Alzheimer's disease and vascular cognitive impairment without relying on post-mortem analysis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590726000019
    Figure 0007590726000019
  • Figure 0007590726000020
    Figure 0007590726000020
  • Figure 0007590726000021
    Figure 0007590726000021
Patent Text Reader

Abstract

Disclosed are radiofluorinated FNDPs and methods of use for PET imaging of soluble epoxyhydrolase (sEH).
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 62 / 331,691, filed May 4, 2016, which is incorporated by reference in its entirety.

[0002] [Federally funded research and development] This invention was made with Government support under Grants NS089437, NS038684, NS060703, and DoD Grant GW130098 awarded by the National Institutes of Health (NIH). The Government has certain rights in this invention. [Background technology]

[0003] Epoxyeicosatrienoic acids (EETs) are important signaling molecules in cerebral vasodilation following neural activity. They also modulate the activity of multiple molecular targets and signaling pathways (Spector and Norris, Am. J. Physiol. Cell Physiol 2009). Soluble epoxide hydrolases (sEHs) are abundantly distributed throughout the mammalian body (Sura et al., J. Histochem. Cytochem, 2008; Marowski et al., Neuroscience, 2009) and catalyze the hydrolysis of EETs to less biologically active molecules (Newman et al., Prog. Lipid. Res., 2005). Over the last decade, sEH has become a pharmaceutical target, and several small molecule sEH inhibitors have been developed. These sEH inhibitors increase levels of EETs, which in turn may provide benefits in a variety of conditions including hypertension, atherosclerosis, inflammation, diabetes, pain, and pulmonary disease, among others (Shen and Hammock, J. Med. Chem., 2012).

[0004] sEH regulation is altered in many diseases, including vascular cognitive impairment (VCI) and stroke, among others. The contribution of cerebrovascular pathology to Alzheimer's disease (AD) and dementia is increasingly being appreciated. Postmortem studies have shown that one-third of dementia patients have coexisting cerebrovascular pathology (White et al., Ann. NY Acad. SCi., 2002; Knopman et al., Arch. Neurol., 2003). A recent report found that sEH activity was 50% higher in subjects with VCI versus age-matched controls (Neslon et al., Prostaglandins Other Lipid. Mediat., 2014). The most common type of VCI is associated with white matter hyperintensities, an early sign of conversion to mild cognitive impairment (Neslon et al., Prostaglandins Other Lipid. Mediat., 2014), which in turn represents a higher risk of developing AD.

[0005] As mentioned above, changes in sEH expression alter the biological effects of EETs. A consistently observed effect of EETs is their ability to prevent apoptosis and other forms of damage after ischemic insults (Iliff and Alkayed, Future neurology, 2009). Various studies have shown that EETs protect the brain during stroke, and inhibition of sEH enhances this effect (Ingraham et al., Curr. Med. Chem, 2011). Patients with aneurysmal subarachnoid hemorrhage are at high risk for delayed cerebral ischemia and stroke (Martini et al., J. Neurosurg., 2014). Patients with the common K55R polymorphism in the sEH gene (Ephx2) showed 30% lower EET levels due to increased she activity (Lee et al., Hum. Mol. Genet., 2006), and they showed a 28.6% mortality rate after stroke compared to 5.3% in control subjects (Martini et al., J. Neurosurg., 2014). Other studies have demonstrated a significant increase in sEH expression in animal models of epilepsy (Hung et al., Brain Behav. Immun., 2015) and Parkinson's disease (Qin et al., Mol. Neurob., 2015).

[0006] In addition to facilitating drug development (Shen and Hammock, J. Med. Chem., 2012), PET imaging agents that noninvasively, repeatedly, and with high resolution target sEH are important in better understanding stroke and dementia, the latter's vascular context. Clinical stroke is primarily assessed by anatomical and functional magnetic resonance imaging, but molecular approaches are limited by the lack of viable radiotracers, as stroke signs are beyond the reach of radiotracers used to measure perfusion with single-photon emission computed tomography (Heiss, Neurosci. Bull., 2014). PET agents for sEH would make it possible to distinguish AD from VCI in vivo without having to rely on postmortem observation of Aβ plaques and neurofibrillary tangles (Morris et al., Eur. J. Nacl. Med. Mol, Imaging, 2015; Couto and Millis, International Journal of Alzheimer's disease, 2015). Summary of the Invention

[0007] In some embodiments, the subject matter of the present disclosure has formula (I): [ka] A compound of the formula: wherein X is selected from the group consisting of F, Br, and I, and radioisotopes thereof; Y is -NR-C(=O)- or -C(=O)-NR-; m is an integer selected from the group consisting of 1, 2, 3, and 4; n is an integer selected from the group consisting of 1, 2, 3, 4, and 5; p is an integer selected from the group consisting of 1, 2, and 3; R is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl ... wherein each R1 is independently the same or different and is selected from the group consisting of hydrogen, halogen, alkoxyl, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted naphthyl, and substituted or unsubstituted biphenyl; and a stereoisomer or a pharmaceutically acceptable salt thereof.

[0008] In another embodiment, the compound of formula (I) has formula (II): [ka] It is a compound of the formula:

[0009] In certain embodiments, the compound of formula (I) further comprises a radioisotope suitable for imaging.

[0010] In certain embodiments, the radioisotope suitable for imaging is: 18 F, 76 Br, 123 I, 124 I, 125 I, and 131 I.

[0011] In an even more particular embodiment, the compound of formula (I) is [ka] It is.

[0012] In another aspect, the presently disclosed subject matter provides a method of imaging soluble epoxide hydrolase (sEH), comprising contacting sEH with an effective amount of a compound of formula (I) and producing an image.

[0013] In some other aspects, the presently disclosed subject matter provides a method of inhibiting soluble epoxide hydrolase (sEH) in the treatment of an sEH-mediated disease, comprising inhibiting sEH by administering to a subject a therapeutically effective amount of a compound of formula (I).

[0014] In yet other aspects, the presently disclosed subject matter provides kits that include a compound of formula (I).

[0015] While certain aspects of the subject matter of the present disclosure have been described above, which are covered in whole or in part by the subject matter of the present disclosure, other aspects will become apparent as the description proceeds in connection with the accompanying examples and figures, as best described hereinafter.

[0016] Having thus broadly described the subject matter of the present disclosure, reference is now made to the accompanying drawings, which are not necessarily drawn to scale. [Brief description of the drawings]

[0017] [Figure 1]Figure 1A shows (A) the synthesis of N-(3,3-diphenylpropyl)-6-fluoronicotinamide (FNDP) and precursor-FNDP for radiolabeling [18F]FNDP; reagents and conditions: (a) 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide, hydroxybenzotriazole (HOBt), N,N-diisopropylethylamine (DIPEA), dimethylformamide (DMF), room temperature. Figure 1B shows (B) the radiosynthesis of 18F-FNDP, a radiotracer for PET imaging of sEH. [Diagram 2] FIG. 1 shows representative sEH inhibitors 1-cyclohexyl-3-dodecyl-urea (CDU) and 12-(3-(adamantan-1-yl)ureido)dodecanoic acid (AUDA), which are known in the art (Shen, Expert. Opin. Ther. Pat., 2010); due to the large hydrophobic domains in the structure, these compounds are considered to be unsuitable leads for the development of PET radiotracers. [Diagram 3] FIG. 1 shows a comparative study of the relative fluorescence of compounds FNDP, nor-fluoro-FNDP (N-(3,3-diphenylpropyl)-nicotinamide), and AUDA; FNDP demonstrated lower nanomolar inhibitory activity against sEH compared to AUDA and nor-fluoro-FNDP. [Figure 4] FIG. 1 shows dose-dependent blockade of 18F-FNDP (0.1 mCi) uptake with the sEH inhibitor nor-fluoro-FNDP (subcutaneous) in the brain of CD-1 mice 60 min after injection of the radiotracer; data are mean %ID / g tissue ± SD (n=3); Abbreviations: Str, striatum; Ctx, cortex; Hip, hippocampus; CB, cerebellum; Blockade curves demonstrate that 18F-FNDP specifically labels sEH binding sites in all brain regions studied; residual binding at the highest dose of blocker corresponds to non-specific binding. [Diagram 5]FIG. 5 shows baseline and blockade of 18F-FNDP (0.1 mCi) uptake in sEH-KO and control C57BL / 65 mice 60 min after injection of the radiotracer; data are mean %ID / g±SD (n=5); blockade utilized the sEH inhibitor nor-fluoro-FNDP (1 mg / kg, subcutaneously). [Figure 6] FIG. 1 shows representative plasma time activity curves (TACs) from a baseline PET study in baboons; a total of 13 brain regions were analyzed, six of which are shown above for clarity. [Figure 7] FIG. 1 shows a comparison of regional time-uptake curves of 18F-FNDP in the same baboon at baseline (top two curves) and after blockade with nor-fluoro-FNDP (2 mg / kg) (bottom two curves) showing a significant decrease in radioactivity in the blockade scans; two representative regions are shown, putamen (squares) and cerebellum (triangles). [Figure 8] FIG. 1 shows a comparison of 18F-FNDP PET regional volume of distribution (VT) between baseline and block scans in 13 brain regions of the baboon brain; data = mean VT ± SD (baseline n=3, block n=1). [Figure 9] Figure 1 shows PET baseline (averaged, 3 scans, top row) and block (single scan, bottom row) parametric VT images of 18F-FNDP in the baboon brain; the PET images are shown with a pseudocolor scale and overlaid with MR images (grayscale) of the baboon brain. [Figure 10] FIG. 13 shows HPLC of representative radioactive metabolites in baboon plasma at 60 min (parent 18F-FNDP-9.5 min, two radioactive metabolites-0.7 min and 6.8 min). [Figure 11] Figure 1: HPLC radiometabolite analysis. Time-% curve of parent 18F-FNDP in baboon plasma; data = mean % parent ± SD, n = 3.

[0018] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] The subject matter of the present disclosure will now be described more fully hereinafter with reference to the accompanying drawings, in which some, but not all, embodiments of the present disclosure are shown. Like reference numerals refer to like elements throughout. The subject matter of the present disclosure may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements. Indeed, many modifications and other embodiments of the subject matter of the present disclosure described herein will come to mind to one skilled in the art to which the present disclosure pertains, having the benefit of the teachings presented in the foregoing description and the accompanying drawings. Therefore, it should be understood that the subject matter of the present disclosure is not to be limited to the specific embodiments disclosed, and that modifications and other embodiments are intended to be included within the scope of the appended claims.

[0020] I. For PET imaging of soluble epoxide hydrolase 18 F-FNDP Soluble epoxide hydrolase (sEH) is a bifunctional enzyme located in the cytosol and peroxisomes that converts epoxides to the corresponding diols and hydrolyzes phosphate monoesters. sEH functions to inactivate epoxyeicosatrienoic acids (EETs), which have vasoactive and anti-inflammatory properties. sEH inhibitors have been explored as drugs to reduce neurological damage after stroke. However, many of the sEH inhibitors to date have large hydrophobic domains, which makes them less viable radiotracers due to potentially high nonspecific binding (Figure 2). In the subject matter of the present disclosure, N-(3,3-diphenylpropyl)-6- 18 F-Fluoronicotinamide ( 18To provide the synthesis, biodistribution, and baboon brain PET imaging of F-FNDP. 18 F-FNDP is a radioactive tracer for sEH that is structurally similar to the potent sEH inhibitor N-(3,3-diphenylpropyl)-nicotinamide, also known as nor-fluoro-FNDP (Eldrup et al., J. Med. Chem., 2009). 18 F-FNDP readily enters mouse and baboon brain and selectively labels sEH with dramatic specificity.

[0021] the current, 18 F-FNDP is the first and only radiotracer with suitable properties for PET imaging of sEH in animal brains.

[0022] A. Compounds of Formula (I) Thus, in some embodiments, the subject matter of the present disclosure is a compound represented by formula (I): [ka] A compound of the formula: wherein X is selected from the group consisting of F, Br, and I, and radioisotopes thereof; Y is -NR-C(=O)- or -C(=O)-NR-; m is an integer selected from the group consisting of 1, 2, 3, and 4; n is an integer selected from the group consisting of 1, 2, 3, 4, and 5; p is an integer selected from the group consisting of 1, 2, and 3; R is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted alkyl ... wherein each R1 is independently the same or different and is selected from the group consisting of hydrogen, halogen, alkoxyl, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted naphthyl, and substituted or unsubstituted biphenyl; and stereoisomers or pharma- ceutically acceptable salts thereof.

[0023] In another embodiment, the compound of formula (I) has formula (II): [ka] It is a compound of the formula:

[0024] In certain embodiments, the compound of formula (I) comprises a radioisotope suitable for imaging. In more particular embodiments, the radioisotope suitable for imaging is 18 F, 76 Br, 123 I, 124 I, 125 I, and 131 In an even more particular embodiment, the radioisotope suitable for imaging is selected from the group consisting of: 18 It's F.

[0025] In an even more particular embodiment, the compound of formula (I) is [ka] It is.

[0026] B. Methods of Using Compounds of Formula (I) for Imaging Soluble Epoxide Hydrolase (sEH) In some embodiments, the presently disclosed subject matter provides a method of imaging soluble epoxide hydrolase (sEH), comprising contacting sEH with an effective amount of a compound of formula (I) and producing an image, wherein the compound of formula (I) comprises: [ka] (Wherein: X is 18 F, 76 Br, 123 I, 124 I, 125 I, and 131I; Y is -NR-C(=O)- or -C(=O)-NR-; m is an integer selected from the group consisting of 1, 2, 3, and 4; n is an integer selected from the group consisting of 1, 2, 3, 4, and 5; R is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted alkylhetero ... R1 is selected from the group consisting of hydrogen, halogen, alkoxyl, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted naphthyl, and substituted or unsubstituted biphenyl; and a stereoisomer or a pharmaceutically acceptable salt thereof.

[0027] In some embodiments, the compound of formula (I) has formula (II): [ka] It is a compound of the formula:

[0028] In certain embodiments, X is 18 It's F.

[0029] In a more particular embodiment, the compound of formula (I) has formula (II): [ka] It is a compound of the formula:

[0030] "Contacting" refers to any act that results in physical contact of at least one compound, including the imaging agent of the presently disclosed subject matter, with sEH. Contacting can include exposing sEH to a sufficient amount of compound to result in contact of at least one compound with sEH. The present method can be performed in vitro or ex vivo by introducing and preferably mixing the compound and sEH in a controlled environment, such as a culture dish or culture tube. The present method can also be performed in vivo, in which case contacting refers to exposing the sEH of a subject to at least one compound of the presently disclosed subject matter, such as by administering the compound to the subject by any suitable route. In accordance with the presently disclosed subject matter, contacting can include introducing and exposing the compound to a site remote from the sEH to be contacted, allowing the subject's bodily functions, i.e., natural (e.g., diffusion) or artificial (e.g., swirling) fluid movement, to result in contact of the compound with sEH.

[0031] By "imaging" it is meant using Positron Emission Tomography (PET) to form images of cells, tissues, tumors, body parts, and the like.

[0032] In other embodiments, the compounds of formula (I) are highly specific for sEH, hi some embodiments, the specificity is up to about 95%.

[0033] In other embodiments, the sEH is in vitro, in vivo, or ex vivo. In yet other embodiments, the sEH is present in a subject.

[0034] In many embodiments of the disclosed methods, the "subject" treated by the disclosed methods is preferably a human subject, although it should be understood that the methods described herein are effective with respect to all vertebrate species, and vertebrate species are intended to be included in the term "subject." Thus, a "subject" can include a human subject for medical purposes, such as treatment of an existing disease or disorder or a preventative treatment to prevent the onset of a disease or disorder, or an animal subject for medical, veterinary, or development purposes. Suitable animal subjects include, but are not limited to, primates, such as humans, monkeys, apes, and the like; bovines, such as cows, bulls, and the like; ovines, such as sheep, and the like; caprines, such as goats, and the like; porcines, such as pigs, boars, and the like; equines, such as horses, donkeys, zebras, and the like; felines, including wild and domestic cats; canines, including dogs; lagomorphs, including rabbits, hares, and the like; and mammals, including rodents, including mice, rats, and the like. The animal may be a transgenic animal. In some embodiments, the subject is a human, including, but not limited to, a fetal subject, a neonatal subject, an infant subject, a juvenile subject, and an adult subject. Additionally, a "subject" may include a patient suffering from or suspected of suffering from a disease or disorder. Thus, the terms "subject" and "patient" are used interchangeably herein. The term "subject" also refers to an organ, tissue, cell, or cell collection derived from a subject.

[0035] In some embodiments, a detectably effective amount of the imaging agent of the disclosed method is administered to a subject. In accordance with the subject matter of the present disclosure, a "detectably effective amount" of an imaging agent is defined as an amount sufficient to generate an acceptable image using equipment available for clinical use. A detectably effective amount of an imaging agent may be administered in two or more injections. A detectably effective amount of an imaging agent may vary depending on factors such as the degree of sensitivity of an individual, the age, sex, and weight of the individual, the idiosyncratic response of the individual, dosimetry, and factors related to equipment and film. Optimization of such factors is well within the level of a person skilled in the art.

[0036] In certain embodiments, the compound of formula (I) is capable of crossing the blood-brain barrier, i.e., the sEH is present in the brain of the subject. In other embodiments, the method is non-invasive.

[0037] As used herein, the term "non-invasive" refers to methods in which no equipment is introduced into the body.

[0038] It is preferable for the compound comprising the imaging agent to localize to the sEH rapidly after administration so as to minimize any side effects to the subject.Thus, in some embodiments, the compound of formula (I) readily enters the brain of a subject.

[0039] In some embodiments, the methods of the disclosure use compounds that are stable in vivo such that substantially all of the injected compound, e.g., greater than 50%, greater than 60%, greater than 70%, greater than 80%, or more preferably greater than 90%, is not metabolized by the body prior to excretion, hi other embodiments, compounds including imaging agents are stable in vivo.

[0040] It is also preferred that the compounds of the presently disclosed subject matter are rapidly cleared from body tissues to prevent long-term exposure to radiation from the radiolabeled compounds administered to the patient.Typically, the compounds of the presently disclosed subject matter are cleared from the body in less than about 24 hours.More preferably, the compounds of the presently disclosed subject matter are cleared from the body in less than about 16 hours, less than 12 hours, less than 8 hours, less than 6 hours, less than 4 hours, or less than 2 hours.

[0041] C. Methods of using compounds of formula (I) to inhibit soluble epoxide hydrolase (sEH) in the treatment of sEH-mediated diseases In other embodiments, the presently disclosed subject matter provides a method of inhibiting soluble epoxide hydrolase (sEH) in the treatment of an sEH-mediated disease, comprising inhibiting sEH by administering to a subject a therapeutically effective amount of a compound of formula (I).

[0042] As used herein, the term "inhibit" refers to reducing or decreasing excess soluble epoxide hydrolase activity found in a subject. The term "inhibit" also refers to reducing, suppressing, attenuating, decreasing, suppressing, or stabilizing the onset or progression of a disease, disorder, or condition. Inhibition can occur, for example, by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or even 100%, as compared to an untreated control subject or a subject without a disease or disorder.

[0043] As used herein, generally, an "effective amount" of an active agent refers to an amount sufficient to produce a desired effect, such as delivering an amount of active agent that can be detected in the brain or used to image, diagnose, and / or treat the brain. A "therapeutically effective amount" of a therapeutic agent refers to the amount of agent necessary to elicit a desired biological response. As will be understood by those skilled in the art, the effective amount of an agent may vary depending on factors such as the desired biological endpoint, the agent delivered, the composition of the pharmaceutical composition, the target tissue, or the target cell. In some embodiments, the term "effective amount" refers to an amount sufficient to reduce or ameliorate the severity, duration, progression, or onset of a disease, disorder, or condition, or one or more symptoms thereof; prevent the progression of a disease, disorder, or condition; cause the regression of a disease, disorder, or condition; prevent the recurrence, onset, onset, or progression of symptoms associated with a disease, disorder, or condition, or enhance or improve the prophylactic or therapeutic effects of another therapy.

[0044] As used herein, active agents may be combined and administered in a single dosage form, simultaneously administered as separate dosage forms, or administered as separate dosage forms administered alternately or sequentially on the same or different days. In one embodiment of the subject matter of the present disclosure, the active agents are combined and administered in a single dosage form. In another embodiment, the active agents are administered in separate dosage forms (e.g., in this case it is desirable to change the amount of one and not the other). The single dosage form may include additional active agents for the treatment of a disease condition.

[0045] In certain embodiments, the soluble epoxide hydrolase-mediated disease is selected from the group consisting of hypertension, atherosclerosis, inflammation, diabetes-related diseases, pain, pulmonary diseases, Alzheimer's disease, vascular cognitive impairment (VCI), and stroke.

[0046] D. Pharmaceutical Compositions and Administration In some embodiments, the present disclosure provides pharmaceutical compositions that include a compound of formula (I) alone or in combination with one or more additional therapeutic agents in a mixture with a pharma- ceutically acceptable excipient. Thus, in some embodiments, the subject matter of the present disclosure provides pharmaceutical compositions that include a compound of formula (I) and a pharma- ceutically acceptable carrier, diluent, or excipient. Those skilled in the art will recognize that the pharmaceutical compositions include pharma- ceutically acceptable salts of the above compounds.

[0047] Pharmaceutically acceptable salts are generally well known to those skilled in the art, and include the salts of active compounds prepared using relatively non-toxic acids or bases, depending on the specific substitution moieties found in the compounds described herein.When the compounds of the present disclosure contain relatively acidic functional groups, it is possible to obtain base addition salts by contacting the neutral form of such compounds with a sufficient amount of desired base, either directly or in a suitable inert solvent, or by replacing the monobasic counterion (base) of ion complex with another by ion exchange.Examples of pharmaceutically acceptable base addition salts include sodium salt, potassium salt, calcium salt, ammonium salt, organic amino salt, or magnesium salt, or similar salts.

[0048] When a compound of the present disclosure contains a relatively basic functional group, it is possible to obtain an acid addition salt by contacting the neutral form of such a compound with a sufficient amount of the desired acid, either neat or in a suitable inert solvent, or by replacing one acidic counterion (acid) of the ionic complex with another by ion exchange. Examples of pharmaceutically acceptable acid addition salts include salts derived from inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrogencarbonic acid, phosphoric acid, monohydrogenphosphate acid, dihydrogenphosphate acid, sulfuric acid, monohydrogensulfate acid, hydroiodic acid, or phosphorous acid, and salts derived from relatively non-toxic organic acids such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, methanesulfonic acid, etc. Also included are amino acid salts, such as arginates, and organic acid salts, such as glucuronic or galacturonic acids (see, e.g., Berge et al, "Pharmaceutical Salts," Journal of Pharmaceutical Science, 1977, 66, 1-19).Certain compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

[0049] Thus, pharma- ceutically acceptable salts suitable for use with the subject matter of the present disclosure include, by way of example and without limitation, acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, carnosate, carbonate, citrate, edetate, edisylate, estrate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsonate, hexylresorcinate, hydroxypropyl ester ... Other pharma- ceutically acceptable salts include, for example, lavamin, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate / diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, or teoclate. Other pharma- ceutically acceptable salts are described, for example, in Remington: The Science and Practice of Pharmacy (2006). th ed.) Lippincott, Williams & Wilkins (2000).

[0050] In certain embodiments, the salt is a tri(hydrocarbyl)ammonium salt or a tetra(hydrocarbyl)ammonium salt. In even more particular aspects, the salt is selected from the group consisting of tri(C1-C8-alkyl)ammonium salts, tetra(C1-C8-alkyl)ammonium salts, triphenylammonium salts, tri(hydroxy-C1-C8-alkyl)ammonium salts, and tetra(hydroxy-C1-C8-alkyl)ammonium salts. In even more particular aspects, the salt is selected from the group consisting of trimethylammonium salts, triethylammonium salts, tri(hydroxyethyl)ammonium salts, tripropylammonium salts, and tri(hydroxypropyl)ammonium salts.

[0051] For therapeutic and / or diagnostic applications, the compounds of the present disclosure may be formulated for a variety of modes of administration, including buccal (sublingual, buccal), oral, sublingual, systemic, and local or regional administration. Techniques and formulations can generally be found in Remington: The Science and Practice of Pharmacy (20th ed.) Lippincott, Williams & Wilkins (2000).

[0052] Such agents may be formulated in liquid (e.g., solutions, suspensions, or emulsions) or solid (capsules or tablets) forms and administered systemically or locally, depending on the particular condition being treated. The agents may be delivered, for example, in time-release, controlled-release, or sustained-delayed release forms, as known to those of skill in the art. Techniques for formulation and administration are described in Remington: The Science and Practice of Pharmacy (2006), supra. th (ed.) Lippincott, Williams & Wilkins (2000). Suitable routes may include oral, buccal, by inhalation spray, sublingual, rectal, transdermal, vaginal, transmucosal, nasal or intestinal administration; parenteral delivery including intramuscular, subcutaneous, intramedullary injection, and intrathecal, direct intraventricular, intravenous, intraarticular, intrasternal, intrasynovial, intrahepatic, intralesional, intracranial, intraperitoneal, intranasal, or intraocular injection or other modes of delivery. In some embodiments, the pharmaceutical composition is administered orally. In some embodiments, the pharmaceutical composition is administered intravenously. In some embodiments, the pharmaceutical composition is administered intramuscularly. In some embodiments, the pharmaceutical composition is administered intrathecally. In some embodiments, the pharmaceutical composition is administered subcutaneously.

[0053] For injection, the agents of the present disclosure may be formulated and diluted in aqueous solutions such as Hanks' solution, Ringer's solution, or physiologically compatible buffers such as physiological saline buffer. For such transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[0054] The use of pharmaceutically acceptable inert carriers to formulate the compounds disclosed herein into a dosage form suitable for systemic administration for carrying out the present disclosure is within the scope of the present disclosure. With the selection of suitable carriers and suitable manufacturing techniques, the compositions of the present disclosure, particularly those formulated as liquids, may be administered parenterally, such as by intravenous injection. The compounds can be easily formulated into a dosage form suitable for oral administration using pharmaceutically acceptable carriers well known in the art. Such carriers allow the compositions of the present disclosure to be formulated as tablets, pills, capsules, liquids, gels, syrups, emulsions, suspensions, etc., for oral ingestion by the subject (e.g., patient) to be treated.

[0055] For nasal or inhalation delivery, the agents of the present disclosure may be formulated by methods known to those skilled in the art and may include, for example and without limitation, solubilizing, diluent, or dispersing agents such as saline; preservatives such as benzyl alcohol; absorption enhancers; and fluorocarbons.

[0056] Pharmaceutical compositions suitable for use in the present disclosure include compositions in which the active ingredient is contained in an amount effective to achieve its intended purpose. Determination of an effective amount is well within the capabilities of one of ordinary skill in the art, especially in light of the detailed disclosure provided herein. Generally, the compounds of the present disclosure are effective over a wide dosage range. For example, in the treatment of adult humans, dosages of 0.01-1000 mg per day, 0.5-100 mg, 1-50 mg per day, and 5-40 mg per day are examples of dosages that may be used. A non-limiting dosage is 10-30 mg per day. The exact dosage will depend on the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, the bioavailability of the compound, the adsorption, distribution, metabolism, and excretion (ADME) toxicity of the compound, and the preference and experience of the attending physician.

[0057] These pharmaceutical compositions may contain, in addition to the active ingredient, suitable pharma- ceutical acceptable carriers, including excipients and auxiliaries, that facilitate the processing of the active compound into a preparation that can be used pharma- ceutically. Preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or liquids.

[0058] Pharmaceutical preparations for oral use can be obtained by combining active compounds with solid excipients, optionally grinding the resulting mixture, and processing the mixture of granules after adding suitable auxiliaries if desired to obtain tablets or dragee cores.Suitable excipients are in particular fillers such as sugars, including lactose, sucrose, mannitol or sorbitol; cellulose preparations, such as corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth gum, methylcellulose, hydroxypropylmethyl-cellulose, sodium carboxymethyl-cellulose (CMC), and / or polyvinylpyrrolidone (PVP: povidone).If desired, disintegrants such as cross-linked polyvinylpyrrolidone, agar, or alginic acid or its salts, such as sodium alginate, can be added.

[0059] Dragee cores are provided with suitable coatings.For this purpose, gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol (PEG) and / or titanium dioxide, lacquer solutions and concentrated sugar solutions that may optionally contain suitable organic solvents or solvent mixtures can be used.Dyes or pigments can be added to the tablets or dragee coatings for identification or to give characteristics to different combinations of active compound doses.

[0060] Orally usable pharmaceutical preparations may include push-fit capsules made of gelatin, as well as soft sealed capsules made of gelatin and plasticizers such as glycerol or sorbitol. Push-fit capsules may contain active ingredients in a mixture with fillers such as lactose, binders such as starch, and / or lubricants such as talc or magnesium stearate, and optionally stabilizers. In soft capsules, active compounds may be dissolved or suspended in suitable liquids such as fatty oils, liquid paraffin, or liquid polyethylene glycol (PEG). In addition, stabilizers may be added.

[0061] E.Kit In yet another embodiment, the subject matter of the present disclosure provides a kit comprising a compound of formula (I). In certain embodiments, the kit provides a packaged pharmaceutical composition comprising a pharma- ceutically acceptable carrier, diluent, or excipient and a compound of the present disclosure. In certain embodiments, the packaged pharmaceutical composition will include a reactive precursor required to produce a compound of the present invention when combined with a radiolabeled precursor. Other packaged pharmaceutical compositions provided by the present invention further include instructions, including at least one of instructions for preparing a compound of the present invention from the provided precursor, instructions for using the composition to image cells or tissues expressing PSMA, or instructions for using the composition to image glutamatergic neurotransmission in patients suffering from stress-related disorders, or instructions for using the composition to image prostate cancer.

[0062] II. Definition Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the subject matter described belongs.

[0063] While the following terms relating to compounds of formula (I) are believed to be well understood by those of skill in the art, the following definitions are provided to facilitate explanation of the subject matter of this disclosure. These definitions are intended to supplement and explain, but not exclude, definitions that would be apparent to one of skill in the art upon review of this disclosure.

[0064] As used herein, the terms substituted (whether or not preceded by the term "optionally") and substituents refer to the ability to change one functional group on a molecule to another functional group (provided that the valences of all atoms are maintained), as recognized by one of skill in the art. When multiple positions in any given structure can be substituted with multiple substituents selected from a particular group, the substituents can be the same or different at each position. Substituents can also be further substituted (e.g., an aryl group substituent can have another substituent, such as another aryl group, which is further substituted at one or more positions).

[0065] Where substituents or linking groups are specified by their conventional chemical formula written from left to right, the substituents or linking groups equally encompass the chemically identical substituents resulting from writing the structure from right to left, e.g., -CHO- is equivalent to -OCH-; -C(=O)O- is equivalent to -OC(=O)-; -OC(=O)NR- is equivalent to -NRC(=O)O-, etc.

[0066] When the term "independently selected" is used, the substituents being referenced (e.g., R groups such as groups R1, R2, or variables such as "m" and "n") can be the same or different. For example, both R1 and R2 can be substituted alkyl, or R1 can be hydrogen and R2 can be substituted alkyl, etc.

[0067] When used herein in reference to a group of substituents, the terms "a", "an" or "a(n)" mean at least one. For example, if a compound is substituted with "an" alkyl or aryl, the compound is optionally substituted with at least one alkyl and / or at least one aryl. Furthermore, if a moiety is substituted with an R substituent, the group may be said to be "R-substituted". If a moiety is R-substituted, the moiety is substituted with at least one R substituent, and each R substituent is optionally different.

[0068] A named "R" or group will generally have the art-recognized structure corresponding to the group having that name, unless otherwise specified herein. For purposes of illustration, certain representative "R" groups listed above are defined below.

[0069] The description of the compounds of the present disclosure is limited by the principles of chemical bonding known to those skilled in the art.Therefore, when a group can be substituted with one or more of several substituents, such substitutions are selected to obtain compounds that are known to those skilled in the art to be intrinsically not unstable and / or prone to instability under ambient conditions, such as aqueous, neutral and some known physiological conditions, according to the principles of chemical bonding known to those skilled in the art.For example, heterocycloalkyl or heteroaryl is bonded to the rest of the molecule via ring heteroatom according to the principles of chemical bonding known to those skilled in the art, so as to avoid compounds that are intrinsically unstable.

[0070] Unless expressly defined otherwise, as used herein, a "substituent" includes a functional group selected from one or more of the following moieties, as defined herein:

[0071] As used herein, the term hydrocarbon refers to any chemical group that contains hydrogen and carbon. The hydrocarbon may be substituted or unsubstituted. As would be known to one skilled in the art, any substitutions must satisfy all valences. The hydrocarbon may be unsaturated, saturated, branched, unbranched, cyclic, polycyclic, or heterocyclic. Exemplary hydrocarbons are further defined herein below and include, for example, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, allyl, vinyl, n-butyl, tert-butyl, ethynyl, cyclohexyl, and the like.

[0072] The term “alkyl,” by itself or as part of another substituent, means, unless otherwise stated, straight (i.e., unbranched) or branched chain, acyclic or cyclic hydrocarbon radicals, or combinations thereof, which may be fully saturated, monounsaturated, or polyunsaturated, and which can include divalent and polyvalent groups having the specified number of carbon atoms (i.e., C1-C2). 10 (C1 means 1 to 10 carbons, including 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 carbons). In certain embodiments, the term "alkyl" refers to C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C31, C42, C43, C54, C56, C67, C68, C79, C80, C81, C82, C83, C84, C85, C86, C87, C88, C99, C90, C91, C92, C93, C94, C95, C96, C97, C98, C99, C10, C11, C12, C 1-20 "alkyl" refers to a hydrocarbon radical derived from a hydrocarbon moiety containing 1 to 20 carbon atoms by the removal of a single hydrogen atom, which may be linear (i.e., "straight chain"), branched, or cyclic, saturated or at least partially unsaturated, and in some cases fully unsaturated (i.e., alkenyl and alkynyl).

[0073] Representative saturated hydrocarbon groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, isopentyl, neopentyl, n-hexyl, sec-hexyl, n-heptyl, n-octyl, n-decyl, n-undecyl, dodecyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, and homologs and isomers thereof.

[0074] "Branched" refers to an alkyl group in which a lower alkyl group, such as methyl, ethyl, or propyl, is attached to a linear alkyl chain. A "lower alkyl" refers to an alkyl group having 1 to about 8 carbon atoms, e.g., 1, 2, 3, 4, 5, 6, 7, or 8 carbon atoms (i.e., C 1-8 "Higher alkyl" refers to an alkyl group having from about 10 to about 20 carbon atoms, e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms. In certain embodiments, "alkyl" refers to an alkyl group having, in particular, C 1-8 In another embodiment, "alkyl" refers to a straight chain alkyl, particularly C 1-8 Refers to branched chain alkyl.

[0075] An alkyl group may be optionally substituted with one or more alkyl group substituents, which may be the same or different ("substituted alkyl"). The term "alkyl group substituent" includes, but is not limited to, alkyl, substituted alkyl, halo, arylamino, acyl, hydroxyl, aryloxyl, alkoxyl, alkylthio, arylthio, aralkyloxyl, aralkylthio, carboxyl, alkoxycarbonyl, oxo, and cycloalkyl. One or more oxygen, sulfur, or substituted or unsubstituted nitrogen atoms may be optionally inserted along the alkyl chain, said nitrogen substituents being hydrogen, lower alkyl (also referred to herein as "alkylaminoalkyl"), or aryl.

[0076] Thus, as used herein, the term "substituted alkyl" includes alkyl groups, as defined herein, in which one or more atoms or functional groups of the alkyl group have been replaced with another atom or functional group (including, for example, alkyl, substituted alkyl, halogen, aryl, substituted aryl, alkoxyl, hydroxyl, nitro, amino, alkylamino, dialkylamino, sulfate, and mercapto).

[0077] The term "heteroalkyl", by itself or in combination with another term, means, unless otherwise specified, a stable linear or branched or cyclic hydrocarbon radical or combination thereof, consisting of at least one carbon atom and at least one heteroatom selected from the group consisting of O, N, P, Si and S, where the nitrogen, phosphorus and sulfur atoms may be optionally oxidized and the nitrogen heteroatom may be optionally quaternized. The heteroatoms O, N, P and S and Si may be located at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Examples include, but are not limited to, -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH 25 -S(O)-CH3, -CH2CH 2- These include S(O)2-CH3, -CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, -CH=CH-N(CH3)-CH3, O-CH3, -O-CH2-CH3, and -CN. Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and CH2-O-Si(CH3)3.

[0078] As noted above, heteroalkyl groups, as used herein, include groups that are attached to the remainder of the molecule via a heteroatom, such as -C(O)NR', ​​-NR'R'', -OR', -SR, -S(O)R, and / or -S(O2)R'. When "heteroalkyl" is followed by a specific heteroalkyl group, such as -NR'R, it will be understood that the terms heteroalkyl and -NR'R'' are not redundant and are not mutually exclusive. Rather, the specific heteroalkyl group is recited to add clarity. Thus, the term "heteroalkyl" should not be construed herein to exclude specific heteroalkyl groups, such as -NR'R''.

[0079] "Cyclic" and "cycloalkyl" refer to a non-aromatic monocyclic or polycyclic ring system of about 3 to about 10 carbon atoms, e.g., 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. Cycloalkyl groups can be optionally partially unsaturated. Cycloalkyl groups can also be optionally substituted with alkyl group substituents, oxo, and / or alkylene, as defined herein. One or more oxygen, sulfur, or substituted or unsubstituted nitrogen atoms can be optionally inserted along the cyclic alkyl chain, the nitrogen substituents being hydrogen, unsubstituted alkyl, substituted alkyl, aryl, or substituted aryl, thus providing a heterocyclic group. Representative monocyclic cycloalkyl rings include cyclopentyl, cyclohexyl, and cycloheptyl. Polycyclic cycloalkyl rings include adamantyl, octahydronaphthyl, decalin, camphor, camphane, and noradamantyl, as well as fused ring systems such as dihydro- and tetrahydronaphthalene.

[0080] The term "cycloalkylalkyl," as used herein, refers to a cycloalkyl group, as defined above, attached to the parent molecular moiety through an alkyl group, also defined above. Examples of cycloalkylalkyl groups include cyclopropylmethyl and cyclopentylethyl.

[0081] The term "cycloheteroalkyl" or "heterocycloalkyl" refers to a non-aromatic ring system, unsaturated or partially unsaturated ring system, such as a 3-10 membered substituted or unsubstituted cycloalkyl ring system, containing one or more heteroatoms, which may be the same or different, selected from the group consisting of nitrogen (N), oxygen (O), sulfur (S), phosphorus (P), and silicon (Si), which may optionally contain one or more double bonds.

[0082] Cycloheteroalkyl rings may be optionally fused or otherwise attached to other cycloheteroalkyl rings and / or non-aromatic hydrocarbon rings. Heterocyclic rings include those having 1 to 3 heteroatoms independently selected from oxygen, sulfur, and nitrogen, where the nitrogen and sulfur heteroatoms may be optionally oxidized and the nitrogen heteroatom may be optionally quaternized. In certain embodiments, the term heterocyclic refers to a non-aromatic 5-, 6-, or 7-membered ring or polycyclic group in which at least one ring atom is a heteroatom selected from O, S, and N (the nitrogen and sulfur heteroatoms may be optionally oxidized), including, but not limited to, bi- or tricyclic groups containing fused 6-membered rings having 1-3 heteroatoms independently selected from oxygen, sulfur, and nitrogen, where (i) each 5-membered ring has 0-2 double bonds, each 6-membered ring has 0-2 double bonds, and each 7-membered ring has 0-3 double bonds, (ii) the nitrogen and sulfur heteroatom may be optionally oxidized, (iii) the nitrogen heteroatom may be optionally quaternized, and (iv) any of the above heterocyclic rings may be fused to an aryl or heteroaryl ring. Representative cycloheteroalkyl ring systems include, but are not limited to, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, quinuclidinyl, morpholinyl, thiomorpholinyl, thiadiazinanyl, tetrahydrofuranyl, and the like.

[0083] The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl", respectively. Additionally, in a heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. The terms "cycloalkylene" and "heterocycloalkylene" refer to the divalent derivatives of cycloalkyl and heterocycloalkyl, respectively.

[0084] Unsaturated alkyl groups are those that have one or more double or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers. Alkyl groups that are limited to hydrocarbon groups are referred to as "homoalkyl."

[0085] More specifically, as used herein, the term "alkenyl" refers to an alkyl group having at least one carbon-carbon double bond formed by the removal of a single hydrogen molecule, C 1-20 Alkenyl refers to a monovalent group derived from a straight-chain or branched hydrocarbon moiety within the range of 1 to 5. Alkenyl groups include, for example, ethenyl (i.e., vinyl), propenyl, butenyl, 1-methyl-2-buten-1-yl, pentenyl, hexenyl, octenyl, allenyl, and butadienyl.

[0086] As used herein, the term "cycloalkenyl" refers to a cyclic hydrocarbon containing at least one carbon-carbon double bond. Examples of cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadiene, cyclohexenyl, 1,3-cyclohexadiene, cycloheptenyl, cycloheptatrienyl, and cyclooctenyl.

[0087] As used herein, the term "alkynyl" refers to a linear or branched C alkyl group of a designated number of carbon atoms containing at least one carbon-carbon triple bond. 1-20 It refers to a monovalent group derived from a hydrocarbon. Examples of "alkynyl" include ethynyl, 2-propynyl (propargyl), 1-propynyl, pentynyl, hexynyl, and heptynyl groups, and the like.

[0088] The term "alkylene," by itself or as part of another substituent, refers to a straight-chain or branched divalent aliphatic hydrocarbon group derived from an alkyl group having from 1 to about 20 carbon atoms, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms. The alkylene group may be straight-chain, branched, or cyclic. The alkylene group may also be optionally unsaturated and / or substituted with one or more "alkyl substituents." Optionally, one or more oxygen, sulfur, or substituted or unsubstituted nitrogen atoms (also referred to herein as "alkylaminoalkyl") may be inserted along the alkylene group, the nitrogen substituent being alkyl as previously described. Exemplary alkylene groups include methylene (-CH2-); ethylene (-CH2-CH2-); propylene (-(CH2)3-); cyclohexylene (-CH6-, ... 10 -);-CH=CH-CH=CH-;-CH=CH-CH2-;-CH2CH2CH2CH2-, -CH2CH=CHCH2-, -CH2CsCCH2-, -CH2CH2CH(CH2CH2CH3)CH2-, (CH2) q -N(R)-(CH2) r-, where q and r are each independently an integer from 0 to about 20, e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, and R is hydrogen or lower alkyl; methylenedioxyl (-O-CH2-O-); and ethylenedioxyl (-O(CH2)2-O-). Alkylene groups can have from about 2 to about 3 carbon atoms, and can even have from 6 to 20 carbons. Typically, alkyl (or alkylene) groups have from 1 to 24 carbon atoms, with groups having 10 or fewer carbon atoms being some embodiments of the present disclosure. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having 8 or fewer carbon atoms.

[0089] The term "heteroalkylene" by itself or as part of another substituent means a divalent group derived from heteroalkyl, exemplified, but not limited to, by -CH-CH-S-CH-CH- and -CH-S-CH-CH-NH-CH-. In heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxo, alkylenedioxo, alkyleneamino, alkylenediamino, etc.). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(O)OR'- represents both -C(O)OR'- and -R'OC(O)-.

[0090] The term "aryl", unless otherwise specified, means an aromatic hydrocarbon substituent which may be a single ring or multiple rings (such as 1-3 rings) which are fused or covalently linked together. The term "heteroaryl" refers to an aryl group (or ring) containing 1-4 heteroatoms selected from N, O, and S (in each separate ring in the case of multiple rings), wherein the nitrogen and sulfur atoms are optionally oxidized and the nitrogen atom is optionally quaternized. Heteroaryl groups may be attached to the remainder of the molecule through a carbon or heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, Examples of aryl and heteroaryl ring systems include 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. The terms "arylene" and "heteroarylene" refer to the divalent forms of aryl and heteroaryl, respectively.

[0091] Briefly, the term "aryl" (e.g., aryloxy, arylthioxy, arylalkyl) when used in combination with other terms includes both aryl and heteroaryl rings as defined above. Thus, the terms "arylalkyl" and "heteroarylalkyl" are meant to include groups in which an aryl or heteroaryl group is bonded to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl, furylmethyl, etc.), including alkyl groups in which a carbon atom (e.g., methylene group) is replaced with, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, etc.). However, the term "haloaryl" as used herein means that the term only includes aryl substituted with one or more halogens.

[0092] When a heteroalkyl, heterocycloalkyl, or heteroaryl contains a specific number of members (eg, "3 to 7 members"), the term "member" refers to a carbon or a heteroatom.

[0093] Additionally, as used herein, the formula: [ka] The structure generally represented by refers to ring structures, for example, but not limited to, 3-carbon, 4-carbon, 5-carbon, 6-carbon, 7-carbon, etc., aliphatic and / or aromatic ring structures, including saturated, partially saturated, and unsaturated ring structures containing substituent R groups, where R may be present or absent, and when present, one or more R groups may each be substituted on one or more available carbon atoms of the ring structure. The presence or absence of an R group and the number of R groups is determined by the value of the variable "n", which is an integer generally having a value ranging from 0 to the number of carbon atoms on the ring available for substitution. In the case of multiple R groups, each R group is substituted on an available carbon of the ring structure rather than on another R group. For example, the above structures, where n is 0-2, include, but are not limited to, [ka] and the like.

[0094] A dashed line representing a bond in a cyclic ring structure indicates that the bond may be either present or absent in the ring, i.e., the dashed line representing a bond in a cyclic ring structure indicates that the ring structure is selected from the group consisting of saturated ring structures, partially saturated ring structures, and unsaturated ring structures.

[0095] JPEG0007590726000012.jpg733 represents the point where a moiety is attached to the rest of the molecule.

[0096] When a named atom of an aromatic ring or heteroaromatic ring is defined as "absent," the named atom is replaced by a direct bond.

[0097] Each of the above terms (e.g., "alkyl," "heteroalkyl," "cycloalkyl and "heterocycloalkyl," "aryl," "heteroaryl," "phosphonate," and "sulfonate," as well as their divalent derivatives) are meant to include both substituted and unsubstituted forms of the indicated radical. Optional substituents for each type of radical are provided below.

[0098] Substituents for monovalent and divalent derivative groups of alkyl, heteroalkyl, cycloalkyl, and heterocycloalkyl (including groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) include, but are not limited to, -OR', =O, =NR', =N-OR', -NR'R'', -SR', -halogen, -Si, in a number ranging from 0 to (2m'+1). may be one or more of a variety of groups selected from R'R''R''', -OC(O)R', -C(O)R', -COR', -C(O)NR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR'-C(O)NR''R''', -NR''C(O)OR', -NR-C(NR'R'')=NR''', -S(O)R', -S(O)R', -S(O)NR'R'', -NRSO2R', -CN and -NO2, where m' is the total number of carbon atoms in such group. R', R'', R''', and R'''' may each independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups. As used herein, an "alkoxy" group is an alkyl that is attached to the remainder of the molecule through a divalent oxygen. When a compound of the present disclosure includes, for example, multiple R groups, each R group is independently selected, as are each R', R'', R''', and R'''' groups when multiples of these groups are present. When R' and R'' are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, -NR'R'' is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl.From the above discussion of substituents, one of skill in the art will understand that the term "alkyl" is meant to include groups that contain carbon atoms bonded to groups other than hydrogen groups, such as haloalkyl (e.g., -CF3 and -CH2CF3) and acyls (e.g., -C(O)CH3, -C(O)CF3, -C(O)CHOCH3, etc.).

[0099] Similar to the substituents described above for alkyl groups, exemplary substituents for the aryl and heteroaryl groups (and their divalent derivatives) are varied and include, for example: halogen, -OR', -NR'R'', -SR', -SiR'R''R''', -OC(O)R', -C(O)R', -COR', -C(O)NR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR'-C(O)NR''R''', -NR''C(O)OR', -NR-C(NR'R''R'')=NR'''', -NR-C(NR'R'')=NR'''-S(O)R', -S(O)R', -S(O) and R', R'', R''', and R'''' may be independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. When a compound of the present disclosure includes, for example, multiple R groups, each R group is independently selected, as are each R', R'', R'''', and R'''' groups when multiples of these groups are present.

[0100] Two of the substituents on adjacent atoms of the aryl or heteroaryl ring are optionally represented by the formula -TC(O)-(CRR') q-U-, where T and U are independently -NR-, -O-, -CRR'- or a single bond, and q is an integer from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -A-(CH2) r A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O)2-, -S(O)2NR'-, or a single bond, and r is an integer of 1 to 4.

[0101] One of the single bonds of the new ring thus formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be a group of the formula -(CRR') s -X'-(C''R'') d -, where s and d are independently integers from 0 to 3, and X' is -O-, -NR'-, -S-, -S(O)-, -S(O)2-, or -S(O)2NR'-. The substituents R, R', R'' and R''' may be independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

[0102] As used herein, the term "acyl" refers to an organic acid group in which the -OH of the carboxyl group is replaced with another substituent and has the general formula RC(=O)-, where R is an alkyl, alkenyl, alkynyl, aryl, carbocyclic, heterocyclic, or aromatic heterocyclic group, as defined herein. Thus, the term "acyl" specifically includes aryl acyl groups, such as 2-(furan-2-yl)acetyl)- and 2-phenylacetyl groups. Specific examples of acyl groups include acetyl and benzoyl. Acyl groups are also intended to include amides, -RC(=O)NR', ​​esters, -RC(=O)OR', ketones, -RC(=O)R', and aldehydes, -RC(=O)H.

[0103] The terms "alkoxyl" or "alkoxy" are used interchangeably herein and refer to a saturated (i.e., alkyl-O-) or unsaturated (i.e., alkenyl-O- and alkynyl-O-) group attached to the parent molecular moiety through an oxygen atom, and the terms "alkyl", "alkenyl", and "alkynyl" are as defined above and include, for example, methoxyl, ethoxyl, propoxyl, isopropoxyl, n-butoxyl, sec-butoxyl, tert-butoxyl, and n-pentoxyl, neopentoxyl, n-hexoxyl, and the like. 1-20 The oxo-hydrocarbon chain may be linear, branched, or cyclic, saturated or unsaturated, within the range of 1 to 20 .mu.m.

[0104] As used herein, the term "alkoxyalkyl" refers to an alkyl-O-alkyl ether, for example, a methoxyethyl or ethoxymethyl group.

[0105] "Aryloxyl" refers to an aryl-O- group, where the aryl group is as described above, including substituted aryl. As used herein, the term "aryloxyl" can refer to phenyloxyl or hexyloxyl, and alkyl, substituted alkyl, halo, or alkoxyl substituted phenyloxyl or hexyloxyl.

[0106] "Aralkyl" refers to the group aryl-alkyl, where aryl and alkyl are as previously described, including substituted aryl and substituted alkyl. Exemplary aralkyl groups include benzyl, phenylethyl, and naphthylmethyl.

[0107] "Aralkyloxyl" refers to an aralkyl-O- group, where the aralkyl group is as previously described. An exemplary aralkyloxyl group is benzyloxyl, C6H5-CH2-O-. The aralkyloxyl group can be optionally substituted.

[0108] "Alkoxycarbonyl" refers to an alkyl-OC(=O)- group. Exemplary alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl, butyloxycarbonyl, and tert-butyloxycarbonyl.

[0109] "Aryloxycarbonyl" refers to the group aryl-OC(=O)-. Exemplary aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.

[0110] "Aralkoxycarbonyl" refers to the group aralkyl-OC(=O)-. An exemplary aralkoxycarbonyl group is benzyloxycarbonyl.

[0111] "Carbamoyl" refers to an amide group of the formula -C(=O)NH2. "Alkylcarbamoyl" refers to the group R'RN-C(=O)- where one of R and R' is hydrogen and the other of R and R' is alkyl and / or substituted alkyl as defined above. "Dialkylcarbamoyl" refers to the group R'RN-C(=O)- where each of R and R' is independently alkyl and / or substituted alkyl as defined above.

[0112] As used herein, the term carbonyldioxyl refers to a carbonate group of formula -OC(=O)-OR.

[0113] "Acyloxy" refers to an acyl-O- group, where acyl is as previously defined.

[0114] The term "amino" refers to the -NH group and also to nitrogen-containing groups known in the art derived from ammonia by replacement of one or more hydrogen radicals by an organic radical. For example, the terms "acylamino" and "alkylamino" refer to certain N-substituted organic radicals having acyl and alkyl substituents, respectively.

[0115] As used herein, "aminoalkyl" refers to an amino group covalently bonded to an alkylene linker. More specifically, as used herein, the terms alkylamino, dialkylamino, and trialkylamino refer to one, two, or three alkyl groups, as defined above, respectively, attached to the parent molecular moiety through a nitrogen atom. The term alkylamino refers to a group having the structure -NHR', where R' is an alkyl group, as defined above, while the term dialkylamino refers to a group having the structure -NR'R'', where R' and R'' are each independently selected from the group consisting of alkyl groups. The term trialkylamino refers to a group having the structure -NR'R''R''', where R', R'', and R''' are each independently selected from the group consisting of alkyl groups. Additionally, R', R'', and / or R''' taken together can optionally be -(CH2) k -, where k is an integer from 2 to 6. Examples include, but are not limited to, methylamino, dimethylamino, ethylamino, diethylamino, diethylaminocarbonyl, methylethylamino, isopropylamino, piperidino, trimethylamino, and propylamino.

[0116] An amino group is -NR'R'', where R' and R'' are typically selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0117] The terms alkylthioether and thioalkoxyl refer to saturated (i.e., alkyl-S-) or unsaturated (i.e., alkenyl-S- and alkynyl-S-) groups attached to the parent molecular moiety through a sulfur atom. Examples of thioalkoxyl moieties include, but are not limited to, methylthio, ethylthio, propylthio, isopropylthio, n-butylthio, and the like.

[0118] "Acylamino" refers to an acyl-NH- group in which acyl is as previously described. "Aroylamino" refers to an aroyl-NH- group in which the aroyl is as previously described.

[0119] The term "carbonyl" refers to the group -C(=O)- and can include aldehyde groups of the general formula RC(=O)H.

[0120] The term "carboxyl" refers to a -COOH group, which is also referred to herein as a "carboxylic acid" moiety.

[0121] As used herein, the term "halo", "halide", or "halogen" refers to fluoro, chloro, bromo, and iodo groups. Furthermore, terms such as "haloalkyl" are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "halo(C1-C4)alkyl" is meant to include, but is not limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

[0122] The term "hydroxyl" refers to the group --OH.

[0123] The term "hydroxyalkyl" refers to an alkyl group substituted with an --OH group.

[0124] The term "mercapto" refers to the group --SH.

[0125] As used herein, the term "oxo" means an oxygen atom that is double bonded to a carbon atom or to another element.

[0126] The term "nitro" refers to the group --NO.sub.2.

[0127] The term "thio" refers to a compound described herein above, wherein a carbon or oxygen atom has been replaced by a sulfur atom.

[0128] The term "sulfate" refers to the -SO4 group.

[0129] As used herein, the term thiohydroxyl or thiol refers to a group of formula -SH.

[0130] More specifically, the term "sulfide" refers to a compound having a group of formula -SR.

[0131] The term "sulfone" refers to a compound having a sulfonyl group, -S(O2)R.

[0132] The term "sulfoxide" refers to a compound with a sulfinyl group -S(O)R.

[0133] The term ureido refers to a urea group of formula -NH-CO-NH2.

[0134] Throughout the specification and claims, a given chemical formula or name is intended to encompass all tautomers, congeners, optical isomers, and stereoisomers, as well as racemic mixtures where such isomers and mixtures exist.

[0135] Certain compounds of the present disclosure may have asymmetric carbon atoms (optical or chiral centers) or double bonds; enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisomeric forms, and individual isomers, which may be defined in terms of absolute stereochemistry as (R)- or (S)-, or for amino acids, D- or L-, are encompassed within the scope of the present disclosure. Compounds of the present invention do not include those known in the art to be too unstable to synthesize and / or isolate. The present disclosure is meant to include compounds in racemic, non-racemic, and optically pure forms. Optically active (R)- and (S)-, or D- and L-isomers, may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When compounds described herein contain olefinic bonds or other geometrically asymmetric centers, it is intended that the compounds include both E and Z geometric isomers, unless otherwise specified.

[0136] Unless otherwise stated, structures depicted herein are meant to include all stereochemical forms of the structure; that is, the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention.

[0137] It will be apparent to one of ordinary skill in the art that certain compounds of the present disclosure may exist in tautomeric forms, and all such tautomeric forms of the compounds are within the scope of the present invention. As used herein, the term "tautomer" refers to one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another.

[0138] Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, the replacement of hydrogen by deuterium or tritium, or 13 C- or 14 Compounds having this structure with the replacement of a carbon with a C-enriched carbon are within the scope of this disclosure.

[0139] The compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may contain, for example, tritium ( 3 H), iodine-125( 125 I) or carbon-14( 14 C). All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure.

[0140] The compounds of the present disclosure may exist as salts. The present disclosure includes such salts. Examples of applicable salt forms include hydrochloride, hydrobromide, sulfate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate (e.g., (+)-tartrate, (-)-tartrate, or mixtures thereof, including racemic mixtures), succinate, benzoate, and salts with amino acids such as glutamic acid. These salts can be prepared by methods known to those skilled in the art. Also included are base addition salts, such as sodium salt, potassium salt, calcium salt, ammonium salt, organic amino salt, or magnesium salt, or similar salts. When a compound of the present disclosure contains a relatively basic functional group, it is possible to obtain an acid addition salt by contacting the neutral form of the compound with a sufficient amount of the desired acid, either neat or in a suitable inert solvent, or by ion exchange. Examples of acceptable acid addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrogen carbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, monohydrogen sulfate, hydroiodic acid, or phosphorous acid, and those derived from organic acids such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-tolylsulfonic acid, citric acid, tartaric acid, methanesulfonic acid, and the like. Also included are salts of amino acids such as arginate, and salts of organic acids such as glucuronic acid or galacturonic acid. Certain specific compounds of the present disclosure contain both basic and acidic functional groups, which allow the compounds to be converted into either base or acid addition salts.

[0141] The neutral forms of the compounds can be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.

[0142] Certain compounds of the present disclosure may exist in solvated forms, including nonsolvated forms and hydrated forms.In general, solvated forms are equivalent to nonsolvated forms and are included within the scope of the present disclosure.Certain compounds of the present disclosure may exist in multiple crystalline or noncrystalline forms.In general, all physical forms are equivalent for the use contemplated by the present disclosure and are intended to be within the scope of the present disclosure.

[0143] In addition to salt forms, the present disclosure provides compounds that are in prodrug form. Prodrugs of the compounds described herein are compounds that undergo easy chemical changes under physiological conditions to provide the compounds of the present disclosure. In addition, prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present disclosure when placed in a transdermal patch reservoir with appropriate enzymes or chemical reagents.

[0144] Following long-standing patent law convention, the terms "a," "an," and "the" refer to "one or more" when used in this application, including the claims. Thus, for example, reference to "an object" includes a plurality of objects unless the context clearly indicates the contrary (e.g., a plurality of objects).

[0145] Throughout this specification and the claims, unless the context indicates otherwise, the terms "comprise," "comprises," and "comprising" are used in a non-exclusive sense. Similarly, the term "include" and its grammatical variations are intended to be non-limiting, such that the recitation of items in a list does not exclude other similar items that may be substituted for or added to the items in the list.

[0146] For purposes of this specification and the appended claims, unless otherwise indicated, all numbers expressing amounts, sizes, dimensions, proportions, shapes, formulations, parameters, percentages, quantities, properties, and other numerical values ​​used in the specification and claims are to be understood as being modified in all instances by the term "about," even if the term "about" does not explicitly appear in conjunction with a value, amount, or range. Thus, unless expressly stated to the contrary, the numerical parameters set forth in the following specification and the appended claims are not, and need not be, precise but may be approximate, and / or larger or smaller, as desired, to reflect tolerances, conversion factors, rounding, measurement errors, and the like, as well as other factors known to those of ordinary skill in the art depending upon the desired properties sought to be obtained by the subject matter of the present disclosure. For example, when referring to a value, the term "about" can mean to encompass variations from the specified amount of ±100% in some embodiments, ±50%, in some embodiments, ±20%, in some embodiments, ±10%, in some embodiments, ±5%, in some embodiments, ±1%, in some embodiments, ±0.5%, and in some embodiments, ±0.1%, as such variations are appropriate in performing the disclosed methods or utilizing the disclosed compositions.

[0147] Additionally, the term "about," when used in connection with one or more numbers or numerical ranges, should be understood to refer to all such numbers inclusive of every number within the range, modifying that range by extending the numerical limits above and below the stated values. Recitation of numerical ranges by endpoints includes all numbers subsumed within that range, for example, all integers including fractions thereof (e.g., a recitation of 1 to 5 includes 1, 2, 3, 4, and 5, and fractions thereof, e.g., 1.5, 2.25, 3.75, 4.1, etc.), and any range within that range. EXAMPLES

[0148] The following examples are included to provide guidance to those skilled in the art for carrying out representative embodiments of the subject matter of the present disclosure. In view of this disclosure and the general level of skill of those skilled in the art, those skilled in the art will understand that the following examples are intended to be merely illustrative, and that numerous changes, modifications, and alterations can be made without departing from the scope of the subject matter of the present disclosure. The following synthetic descriptions and specific examples are intended for illustrative purposes only, and should not be construed as limiting the making of the compounds of the present disclosure by other methods.

[0149] Example 1 overview Soluble epoxide hydrolase (sEH) is a bifunctional enzyme located in the cytosol and peroxisomes that converts epoxides to the corresponding diols and hydrolyzes phosphate monoesters. sEH functions to inactivate epoxyeicosatrienoic acids (EETs), which have vasoactive and anti-inflammatory properties. sEH inhibitors have been explored as drugs to reduce neurological damage after stroke. The subject of the present disclosure is N-(3,3-diphenylpropyl)-6-(2-phenylpropyl)-2-(2-phenylpropyl)-1,2-diphenyl-2-(2-phenylpropyl)-1,3-diphenyl-2-(2-phenylpropyl)-1,4-diphenyl-2-(2-phenylpropyl)-1,5-diphenyl-2-(2-phenylpropyl)-1,6-diphenyl-2-(2-phenylpropyl)-1,7-diphenyl-2-(2-phenylpropyl)-1,8-diphenyl-2-(2-phenylpropyl)-1,9-diphenyl-2-(2-phenylpropyl)-1,10-diphenyl-2-(2-phenylpropyl)-1,2 ...3-diphenyl-2-(2-phenylpropyl)-1,4-diphenyl-2-(2-phenylpropyl)-1,5-diphenyl-2-(2-phenylpropyl)-1,6-diphenyl-2-(2-phenylpropyl)-1,7-diphenyl-2-(2 18 F-Fluoronicotinamide ( 18 F-FNDP) and analogs and derivatives thereof.

[0150] 18 F-FNDP was synthesized from the corresponding bromo precursor. 18 The sEH inhibitory activity of F-FNDP was measured using a sEH inhibitor screening assay kit (Cayman Chemical, Michigan). Biodistribution was performed in CD-1 mice. Binding specificity was assayed in CD-1 mice, sEH knockout mice, and Anubis baboons by pretreatment with sEH inhibitors that block sEH binding. Dynamic PET imaging with arterial blood sampling was used to measure the volume of distribution (V T ) was used to quantitate local tracer binding in three baboons.18 The metabolism of F-FNDP was assessed using high performance liquid chromatography (HPLC).

[0151] 18 F-FNDP(K i =1.73 nM) was prepared in one step using an automated radiosynthesis module with a radiochemical yield of 14 ± 7%, specific activities ranging from 888-3,774 GBq / μmol, and radiochemical purity of >99%. Preparation time was approximately 75 min. In CD-1 mice, at an injected dose with a maximum uptake of 5.2% per gram of tissue, regional uptake followed the striatum > cortex > hippocampus > cerebellum pattern consistent with the known brain distribution of sEH. Blockade of 80-90% was demonstrated in all brain regions. The lowest radiotracer uptake was in sEH-KO mice. PET baboon brain distribution was consistent with that seen in mice showing significant blockade (95%) in all regions, suggesting that sEH-mediated 18 F-FNDP uptake is shown. In baboon plasma, 20% of the parent compound was present 90 min after injection, with two hydrophilic metabolites identified.

[0152] 18 F-FNDP can be synthesized with suitable radiochemical yield, high specific activity, and purity. In vivo imaging experiments have demonstrated that 18 It was demonstrated that F-FNDP specifically targets sEH in mouse and non-human primate brain. 18 F-FNDP is a promising PET radiotracer that may be useful in understanding the role of sEH in various diseases affecting the central nervous system.

[0153] Example 2 Materials and Methods All reagents were used directly as commercially obtained from Sigma-Aldrich (St. Louis, MO). Nor-fluoro-FNDP was prepared as previously described (Edrup et al. J. Med. Chem. 2009). Column flash chromatography was performed using E. Merck silica gel 60F (230-400 mesh) (Sigma-Aldrich). NMR spectroscopy was performed in CDCl3 on a Bruker-500 MHz NMR spectrometer (Billerica, MA). 1 H NMR spectra were recorded (δ H (Based on 0 ppm internal Me4Si). The high performance liquid chromatography (HPLC) system consisted of two Varian ProStar pumps (Palo Alto, CA), a single Rheodyne® Model 7725i manual injector, a ProStar325UV-Vis variable wavelength detector, and a BioScan Flow-Count radioactivity detector (Poway, CA). Analytical semi-preparative chromatography was performed using a Phenomenex Luna C-18 10 μm column (4.6x250mm and 10x250mm, respectively) (Torrance, CA). Laboratory animal protocols were approved by the Animal Care and Use Committee of the Johns Hopkins Medical Institutions.

[0154] synthesis N-(3,3-diphenylpropyl)-6-fluoronicotinamide (FNDP). 3,3-diphenylpropan-1-amine (105.5 mg, 0.5 mmol) was added to a solution of 6-fluoronicotinic acid (70.5 mg, 0.5 mmol) in 3 mL of N,N-dimethylformamide, followed by 1-hydroxybenzotriazole (135 mg, 1 mmol), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (191 mg, 1 mmol), and diisopropylethylamine (195.5 mg, 1.5 mmol). The reaction was stirred at room temperature for 48 h, the solvent was evaporated under vacuum, and the residue was separated by flash LC (silica gel, hexane-ethyl acetate 5:1→2:1) to give the desired product FNDP (121 mg, 72%). 1 H NMR (CHCl3-d3, 500 MHz) δ8.32 (d, J=2.5 Hz, 1H), 8.10-8.06 (m, 1H), 7.27-7.24 (m, 8H), 7.25 (m, 2H), 7.01-6.98(m, 1H), 5.92 (broad s, 1H), 4.07 (t, J=8Hz, 1H), 3.57 (m, 2H), 2.48 (m, 2H).

[0155] 6-Bromo-N-(3,3-diphenylpropyl)nicotinamide (Precursor-FNDP). Precursor-FNDP was prepared similarly to FNDP using 6-bromonicotinic acid as the starting material. Yield: 59%. 1 H NMR (CHCl3-d3, 500 MHz) δ8.45 (d, J=2.5 Hz, 1H), 7.79 (m, 1H), 7.56 (d, J=8Hz, 1H), 7.37-7.32 (m, 8H), 7.27-7.24 (m, 2H), 5.92 (broad s, 1H), 4.07 (t, J=9Hz, 1H), 3.56 (m, 2H), 2.49 (m, 2H).

[0156] radioactive synthesis N-(3,3-diphenylpropyl)-6- 18 F-Fluoronicotinamide (18 F-FNDP) at the General Electric PETtrace cyclotron 18 Obtained by proton bombardment of O-water 18 F-fluoride, 2 mg of K2CO3 in 0.4 mL of water, and 15-20 mg of Kryptofix® 222 in 2 mL of acetonitrile were added to a GE MicroLab module reaction vessel (Cincinnati, OH). The mixture was azeotroped at 140° C. under a stream of argon after adding 2 mL of CH3CN. A solution of precursor-FNDP (2 mg) in DMSO (0.8 mL) was added to the reaction vessel along with the mixture heated at 160° C. for 12 min. The reaction mixture was cooled, diluted with 0.7 mL of water, and injected into a reversed-phase semi-preparative high performance liquid chromatography (HPLC) column. The radioactive product peak was collected in 50 mL of HPLC grade water. The aqueous solution was transferred through an activated Waters C-18 Sep-Pak Light cartridge (Milford, MA). After washing the cartridge with 10 mL of saline, the product was eluted with 1 mL of ethanol through a 0.2 μM sterile filter into a sterile pyrogen-free container, and 10 mL of 0.9% saline was added through the same filter. The final product was then 18 F-FNDP was analyzed by analytical HPLC to determine radiochemical purity and specific activity. Total preparation time, including quality control, was 75 min. Semi-preparative HPLC conditions: Luna C18, 10 microns, 10x250mm; mobile phase: 45:55 (acetonitrile: 0.1M ammonium formate in water); flow rate 10mL / min; UV-254nm; retention times 13 and 21 min (FNDP and precursor-FNDP, respectively). Analytical HPLC conditions: Luna C18, 10 microns, 4.6x250mm; mobile phase: 55:45 (acetonitrile: 0.1M ammonium formate in water); flow rate 3mL / min; UV-254nm; retention times 3.9 and 6.5 min (FNDP and precursor-FNDP, respectively).

[0157] in vitro studies In vitro inhibition of sEH with FNDP. The inhibitory activity of FNDP, nor-fluoro-FNDP, analogs of FNDP, and known inhibitors of sEH (Eldrup et al., J. Med. Chem., 2009) was measured using an sEH inhibitor assay kit (Cayman Chemical, Michigan). Briefly, the IC of sEH inhibitors was determined by measuring the inhibition of the hydrolysis of (3-phenyl-oxiranyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester by sEH. 50 AUDA (Cayman Chemical, Michigan), a known inhibitor of sEH (Imig et al., Hypertension, 2005), was used as a positive control. All reactions were performed in triplicate and data were analyzed using GraphPad Prism (GraphPad Software, San Diego, California) to determine the inhibition constant (K i value).

[0158] In mice 18 Biodistribution studies using F-FNDP Baseline Study in CD1 Mice. Male CD-1 mice weighing 25-27 g from Charles River (Wilmington, MA) were used. Animals were dosed with 3.7 MBq (0.1 mCi) in 0.2 mL saline. 18 Mice were sacrificed by cervical dislocation 5, 15, 30, 60, and 90 min after injection of F-FNDP (specific activity = 814 GBq / μmol (22,000 mCi / μmol) into the lateral tail vein (n = 3). Brains were removed and dissected on ice. The striatum, cortex, hippocampus, hypothalamus, cerebellum, and remaining brain were weighed and their radioactivity content was determined in a γ-counter LKB / Wallac 1283 CompuGamma CS (Perkin Elmer, Bridgeport, CT). Aliquots of the injectate were prepared as standards and their radioactivity content was determined along with tissue samples. The percent injected dose per gram of tissue (%ID / g tissue) was calculated.

[0159] In CD1 mice18 Blockade of F-FNDP binding. In vivo binding specificity (blocking) studies were performed 15 min after subcutaneous administration of various doses (0 mg / kg, 0.03 mg / kg, 0.3 mg / kg, 1 mg / kg, 3 mg / kg) of nor-fluoro-FNDP, with 3.7 MBq (0.1 mCi) 18 This was performed by IV injection of F-FNDP (n = 3). Ninety minutes after administration of the radiotracer, the animals were sacrificed by cervical dislocation, and brain tissue was harvested and its radioactivity content was determined.

[0160] in sEH knockout (SEH-KO) mice and C57BL / 6 control mice 18 Baseline and blocking studies of F-FNDP. 18 Baseline and blocking studies with F-FNDP (nor-fluoro-FNDP, 1 mg / kg, subcutaneous) were performed similarly to the above study. sEH-KO mice (Ephx2 gene deletion; Jackson Labs) and C57Bl / 6 background mice were studied (n=5). All animals were sacrificed 60 min after radiotracer injection.

[0161] The sample sizes for CD-1 and sEH-KO mice in the baseline and blocking studies were 3 and 5, respectively, which corresponds to a statistical power of >0.9 as calculated by G*Power, v.3.1.9.2 freeware.

[0162] Baboon PET and radiometabolite studies Baseline and intercept dynamic PET experiments (90 min) were performed in three male baboons (Bacopa anubis) weighing 23.9, 25.0, and 28.2 kg using a high-resolution research tomograph (HRRT, CPS Innovations, Inc., Knoxville, Tennessee). Briefly, dynamic PET acquisitions were performed using a 248 MBq (6.7 mCi) MRI scan. 18Blockade scans in the same baboons were performed using an intravenous injection of nor-fluoro-FNDP (2 mg / kg, 307 MBq (8.3 mCi)). 18 An intravenous bolus of F-FNDP (specific activity 1420 GBq / μmol (38,386 mCi / μmol), carrier mass = 0.0025 μg / kg) was given subcutaneously 1 h before the start of the scan. Radioactive metabolite analysis in baboon arterial blood was performed under general conditions as previously published (Hilton et al., Nucl. Med. Biol., 2000).

[0163] Baboon PET studies. PET experiments were performed in male baboons (Baboon anubis) weighing 28.2 kg using a high-resolution research tomography system (HRRT, CPS Innovations, Inc., Knoxville, TN). Animals underwent one baseline PET scan and one block scan 3 weeks later. Animals were fasted for 12 hours before each PET study. Anesthesia was induced with intramuscular ketamine (7.5-10 mg / kg) and maintained with a continuous intravenous infusion with a protocol of 0.3-0.4 mg / kg / min throughout the PET experiments. One venous catheter was inserted for radioligand injections and one arterial catheter was inserted to obtain arterial blood samples. Measurements of arterial plasma input function were performed with the collection of 43 blood samples in a 90-minute series of dynamic PET scans. The baboons were also intubated to allow easy breathing and circulatory volume was maintained by constant infusion of isotonic saline. Physiologic vital signs, including heart rate, blood pressure, electrocardiogram, and oxygen saturation, were continuously monitored throughout the study.

[0164] The animal was placed in the PET scanner with its head immobilized in a thermoplastic mask. Rotation [ 137 A 6-minute transmission scan was obtained using a [Cs] cesium source. Then, 248 MBq (6.7 mCi) 18A 90-minute dynamic PET acquisition was started in 3D list mode simultaneously with the intravenous bolus administration of F-FNDP (specific activity 2634 GBq / μmol (71,177 mCi / μmol)). In the block scan, nor-fluoro-FNDP (2 mg / kg) was administered at 307 MBq (8.3 mCi). 18 An intravenous bolus of F-FNDP (specific activity 1420 GBq / μmol (38,386 mCi / μmol) was given subcutaneously 1 hour prior to the start of 90-min dynamic PET imaging.

[0165] PET image reconstruction. The 90 min PET list-mode data were split into 22 frames (three 20 s, two 30 s, two 1 min, three 2 min, eight 5 min, and four 10 min frames). The data were then reconstructed using an iterative ordered subsets expectation maximization (OS-EM) algorithm (6 iterations, 16 subsets) with corrections for radioactive decay, dead time, attenuation, scattering, and disorder. Prior to the emission scan, 137 Attenuation maps were generated from 6-min transmission scans performed with a [Cs] cesium point source. The reconstructed image volumes each had a size of 1.22 mm 3 , consisted of a cubic voxel with through dimensions of 31 cm x 31 cm (longitudinal) and 25 cm (axial).

[0166] Brain volumes of interest (VOIs) and regional time-activity curves (TACs): The software package PMOD (v3.3, PMOD Technologies Ltd, Zurich, Switzerland) was used for the next image processing and subsequent dynamic analysis steps. Previously acquired baboon brain MRI T1-weighted images were co-registered to the reconstructed dynamic PET images acquired in this study. Thirteen representative baboon brain VOIs were defined, including the frontal gyrus, temporal gyrus, thalamus, hippocampus, caudate nucleus, putamen, amygdala, globus pallidus, insula, hypothalamus, cerebellum, corpus callosum, and white matter, by manually matching the co-registered MRIs to the INIA19 template and the NeuroMaps Atlas for segmentation and spatial normalization of primate brain images (Rohlfing et al., Frontiers in neuroinformatics, 2012). These VOIs were then used to generate regional brain TACs for both baseline and blocked PET scans.

[0167] PET dynamic analysis: Regional brain distribution volume (V T ) calculation: Based on the regional TAC obtained above, 18 F-FNDP binding was quantitatively characterized using metabolite-corrected arterial plasma input functions. In accordance with common terminology for in vivo imaging of reversibly binding radioligands (Innis et al., J. Cereb. Blood Flow Metab., 2007), and lacking a fixed reference region, the primary evaluation criterion was the regional distribution volume (V), defined as the ratio of the radioligand concentration in regional brain tissue to the radioligand concentration in plasma at equilibrium. T ) Regionality V T is proportional to the receptor concentration in the defined VOI. T was calculated for each VOI using the Logan method (Logan et al., J. Cereb. Blood Flow Metab., 1990).

[0168] HPLC analysis of radioactive metabolites: For determination of plasma radioactivity, baboon arterial blood samples were taken throughout the PET study, initially at very short (<5 sec) intervals and then at increasingly longer intervals. Selected samples taken at 0, 5, 10, 20, 30, 60, and 90 min were analyzed using the general method described above (Hilton et al., Nucl. Med. Biol., 2000). 18 The presence of F-FNDP and its radioactive metabolites was analyzed by HPLC (Figure 9). Briefly, 3 mL of plasma in 8 M urea was passed through a collection column (19x4.6 mm Strata-X, Phenomenex, Torrance, CA) followed by 1% acetonitrile in water to wash the plasma proteins from the column. The effluent from the collection column, containing only the highly polar components, was passed through a dual BGO detector (Bioscan, Washington DC). The solvent was then switched to a mixture of 60% acetonitrile / 40% 0.1 M aqueous ammonium formate pH=2.7 (2 mL / min) to elute the radiolabeled components bound to the collection column onto the analytical column (Gemini C18, 4.6x254 mm, Phenomenex, Torrance, CA).

[0169] Example 3 chemistry N-(3,3-diphenylpropyl)-6-fluoronicotinamide (FNDP) and N-(3,3-diphenylpropyl)-6-bromonicotinamide (precursor-FNDP) were synthesized in high yields (59-72%) (Figure 1A). The molecular structures of FNDP and precursor-FNDP were confirmed by NMR analysis.

[0170] 18 F-FNDP was generated by nucleophilic radiofluorination of the bromo precursor-FNDP in radiochemical yields of 14 ± 7% (n = 6) (not decay corrected), with specific activities at the end of the synthesis ranging from 888-3,774 GBq / mmol (24,000-102,000 mCi / μmol) and radiochemical purity of >99% (Figure 1B). 18F-FNDP was prepared as a sterile, non-pyrogenic solution in 7% ethanolic saline with a pH of 5.5-6.

[0171] FNDP has IC comparable to that of the potent sEH inhibitor AUDA. 50 and K. i The IC values ​​for FNDP, nor-fluoro-FNDP, and AUDA were 50 The values ​​were 8.66 ± 0.06, 18.53 ± 0.04, and 6.48 ± 0.05 nM, respectively (Figure 3). The corresponding K i The values ​​were 1.73, 3.71, and 1.30 nM, respectively.

[0172] Example 4 Regional brain distribution study in CD-1 mice Baseline study. In CD-1 mouse brain 18 The regional distribution of F-FNDP is shown in Table 1.

[0173] [Table 1]

[0174] In CD-1 mice 18 F-FNDP-Dose-Increasing Block of sEH Binding Specificity. The sEH inhibitor nor-fluoro-FNDP inhibited sEH binding in all studied brain regions (striatum, hippocampus, cortex, and cerebellum) 60 min after injection in a dose-dependent manner. 18 F-FNDP binding was blocked (Fig. 4). At the highest blocker dose of 3 mg / kg, radioactivity uptake was reduced by 90% in the striatum, hippocampus, and cortex, and by 75% in the cerebellum.

[0175] In SEH-KO and C57BL6 control mice 18 Baseline and blocking studies of F-FNDP. In baseline experiments 60 min after injection, 18Regional uptake of F-FNDP was approximately 1% of the injected dose per gram of tissue (%ID / g) in the striatum, hippocampus, and cortex, and 0.5%ID / g in the cerebellum (Figure 5). Blockade experiments in C57BL6 mice showed that 18 Brain uptake of F-FNDP was reduced to ~0.2% ID / g tissue in all study areas. In sEH-KO mice, 18 Regional brain uptake of F-FNDP was similar in baseline (0.11-0.12% ID / g) and blockade (0.10-0.11% ID / g) experiments (Fig. 5 ).

[0176] Example 5 PET imaging in the olive baboon High and heterogeneous radioactivity uptake in the baboon brain as evidenced by representative regional TACs. 18 This was observed during the baseline scan after a bolus administration of F-FNDP (Figure 6). Global TAC peaked approximately 5 min after injection, with peak SUVs ranging from 2.5 to 4.0 g / mL. The peak SUV for the whole brain was 3.2 and gradually decreased to 1.8 at the end of the 90 min dynamic scan. The highest accumulation of radioactivity occurred in regions such as the putamen, insula, frontal cortex, and amygdala, with lower uptake seen in the white matter and cerebellum. Notably, the time-activity curve for the cerebellum declined more rapidly than the other study regions (Figure 6).

[0177] V T Of the 13 brain volumes of interest examined, the highest radioligand binding occurred in the insula, putamen, caudate, and amygdala, as quantified using (V T >10.0), and moderate uptake in the frontal / temporal gyrus, hippocampus, and globus pallidus (V T >8.3), followed by the corpus callosum, white matter, hypothalamus, and thalamus (V T >7.2). The lowest binding occurred in the cerebellum, V T was 6.97.

[0178] TAC comparisons between baseline and blockade studies are shown in Figure 7. During the blockade study, regional TAC peaked much earlier, approximately 1 min after injection, with a whole-brain mean peak SUV of 2.3 g / mL, and rapidly declined to a mean SUV of only 0.18 g / mL (10%) of baseline values ​​by the end of the 90-min scan. T When quantified by V T <0.8 and baseline V T The decrease was greater than 90% when compared to baseline values. The decrease was comparable between high and low connectivity regions identified during the baseline study. For example, the insula and amygdala showed a 95% decrease, whereas the cerebellum showed a 93% decrease (Figure 8). Parameter V T Images were generated of both baseline and blocking scans for comparison (Figure 9).

[0179] Blockade and baseline baboon studies 18 The specific activity of the F-FNDP doses ranged from 1420 GBq / μmol to 2634 GBq / μmol. Because the specific activity was so high, the corresponding FNDP carrier mass was only 0.0011-0.0025 μg / kg, which is six orders of magnitude smaller than the nor-fluoro-FNDP blocker dose (2 mg / kg). Without wishing to be bound by any one particular theory, it is therefore assumed that the specific activity variability does not affect the results of this study.

[0180] Radioactive metabolite analysis of blood samples from baboons using reversed-phase high-performance liquid chromatography (RP-HPLC) revealed that the parent compound 18 It was shown that F-FNDP was metabolized to two hydrophilic species (Figure 10). The combined radioactive metabolites in plasma reached 80% of the value in baboons 90 min after injection (Figures 10 and 11).

[0181] Example 6 Summary and Discussion Due to the lack of available radiotracers, only about 39 of the hundreds of known binding sites (receptors and enzymes) in the human brain have been imaged by PET (CNS Radiotracers Table). Until now, sEH was one of many binding sites lacking a specific PET radiotracer. A significant number of sEH inhibitors have been developed by researchers in pharmaceutical industry and academia, opening up a wide opportunity for the development of sEH PET radiotracers. However, many potent sEH inhibitors have large hydrophobic domains, which makes them less viable radiotracers due to potentially high nonspecific binding (Figure 2).

[0182] In the presently disclosed subject matter, we have synthesized N-(3,3-diphenylpropyl)-6-fluoronicotinamide (FNDP, FIG. 1A), a potent sEH inhibitor with molecular properties (logP of 2.9 and molecular weight MW of 334 Da) that are optimal for a brain PET radiotracer (Horti et al., Springer, 2014). FNDP was synthesized by Boehringer Ingelheim as an sEH inhibitor (human IC 50 7 nM) (Eldrup et al., J. Med. Chem., 2009), which has improved "drug-like" characteristics and is structurally similar to the sEH inhibitor N-(3,3-diphenylpropyl)-nicotinamide (nor-fluoro-FNDP), used herein as the lead compound for the development of FNDP and as an inhibitor in animal studies. In vitro assays demonstrated that FNDP is an sEH inhibitor with higher potency than the lead nor-fluoro-FNDP and comparable potency to the general sEH inhibitor AUDA (Figure 3).

[0183] FNDP contains a fluorine atom at position 2 of the pyridine ring, which is activated for nucleophilic substitution reactions, and is the same as the previously developed Br-pyridine. 18 It can be easily radiofluorinated via the corresponding bromo precursor under standard conditions for exchange with F-pyridine (Gao et al., J. Med. Chem., 2008). 18F-Fluoronicotinamide ( 18 Radiosynthesis of F-FNDP was carried out in a conventional FDG-radiochemistry module by nucleophilic radiofluorination of precursor-FNDP (Figure 1B), followed by semi-preparative HPLC separation and formulation of the final radiolabeled product as a sterile, non-pyrogenic solution in saline. Radiotracers with very high specific radioactivity and radiochemical purity were prepared. The precursor-FNDP was easily separated by preparative HPLC and the final product 18 In F-FNDP, it could not be detected by analytical HPLC.

[0184] Mouse studies. In CD-1 mice, 18 F-FNDP showed a heterogeneous brain uptake pattern, which paralleled the expected regional sEH expression in mouse brain (Marowsky et al., Neuroscience, 2009). Peak uptake was 5.2%ID / g 5 min after injection, followed by a rapid decline. Its brain uptake is considered reasonably high, as an uptake of 1%ID / g has traditionally been used as the minimum standard for selection of an investigational CNS radiotracer in our PET center. Of the brain regions studied, 18 The highest accumulation of F-FNDP radioactivity occurred in the striatum, cortex, hippocampus, and remaining brain, while lower but significant radioactivity was seen in the hypothalamus and cerebellum (Table 1). Mouse brain distribution was comparable to in vitro data (Marowsky et al., Neuroscience, 2009).

[0185] 18 To demonstrate the specificity of F-FNDP binding, two types of studies were performed: dose-escalating blockade in CD-1 mice and biodistribution in sEH knockout (sEH-KO) mice. 18Regional brain uptake of F-FNDP was highly sensitive to increasing doses of the sEH inhibitor nor-fluoro-FNDP (Figure 4). The binding blocked in CD-1 mouse brain appears to be specific (90% in striatum, hippocampus, and cortex), whereas the remaining binding at high doses of the inhibitor appears to be nonspecific (10%). These findings support the conclusion that in mouse brain 18 We show that F-FNDP uptake is highly specific and mediated by sEH. No regions of low sEH binding were revealed in this study. The 75% blockade of radioactivity in the cerebellum coincided with the expression of sEH in this region (Marowsky et al., Neuroscience, 2009), suggesting that the cerebellum may not be used as a reference in the mouse brain.

[0186] As a further test of binding specificity, we utilized sEH-KO mice and control animals with the same genetic background (C57BL / 6) (Sinal et al., J. Biol. Chem., 2000). Because sEH-KO mouse brains lack sEH (Qin et al., Mol. Neurobiol., 2015), we hypothesized that the binding specificity of sEH-KO mice was significantly increased in these mice. 18 F-FNDP binding was expected to be nonspecific and differences in uptake between sEH-KO and control brains would represent specific sEH binding. 18 F-FNDP uptake was compared in baseline experiments in sEH-KO and control animals (C57BL / 6) 60 min after injection of the radiotracer (Figure 5). Compared to controls, sEH-KO mice showed 18 There was a marked reduction (approximately 90%) in F-FNDP uptake. High control / sEH-KO ratios were demonstrated in all tested regions (10.3-striatum, 9.4-cortex, 9.2-hippocampus, 4.8-cerebellum). Furthermore, in sEH-KO mice 18 The reduction in F-FNDP uptake was negligible in blocking studies utilizing the sEH inhibitor nor-fluoro-FNDP (Figure 4). 18We showed that any nonspecific binding of F-FNDP to other proteins, such as the product of the Ephx1 gene (microsomal epoxide hydrolase) (Marowsky et al., Neuroscience, 2009), was negligible in sEH-KO brains. In C57BL / 6 controls, we found that the blocking effect (approximately 80%) (Figure 5) was very similar to that in CD-1 mice (Figure 4).

[0187] Mouse studies have shown 18 We demonstrated that F-FNDP readily penetrates the brain (peaking at 5% ID / g) and labels brain sEH with a high degree of specificity (80-90%) in two strains of control mice (CD-1 and C57BL / 6). Consistent with the low expression of sEH in the KO animals, F-FNDP in sEH-KO mice was significantly higher than that in control mice (CD-1 and C57BL / 6). 18 Brain uptake of F-FNDP is 10-fold lower than controls and is essentially nonspecific.

[0188] Baboon PET imaging. High and rapid heterogeneous radioactivity uptake in the baboon brain was demonstrated in three different animals at three baseline 18 This was observed during F-FNDP PET scan (Figure 9). 18 The regional distribution of F-FNDP is consistent with semiquantitative assessment of sEH expression in human (Sura et al., J. Histochem. Cytochem, 2008) and mouse brain (Marowsky et al., Neuroscience, 2009). Regional TAC confirmed the characteristics of optimal reversible PET radioligand binding. Notably, in the baboon brain 18 The washout rate of F-FNDP (Fig. 6) was not as rapid as that in mouse brain (Table 1) and was robust to mathematical modeling (see below).

[0189] Blocking PET studies 18 We showed that F-FNDP labeled sEH with very high specificity in the baboon brain (Figures 7, 8, and 9). Blockade was observed in all baboon brain regions examined, including the cerebellum.

[0190] Soluble epoxide hydrolase inhibitors may increase peripheral vasodilation and reduce blood pressure, which in turn may increase cerebral blood flow and affect radiotracer delivery. To investigate this possibility, the kinetics of the radiotracer was modeled using a standard two-tissue, three-compartment model, which allows reliable estimation of the transfer rate constant (K1) from arterial plasma to tissues. The mean K1 values ​​at baseline and blockade were 0.18 and 0.14 ml / cm, respectively. 3 / min, a difference of 23%. It was observed that the K1 change from baseline to blockade was T It has been demonstrated that the significant decrease (>90%) in the 18 It was confirmed that F-FNDP labels sEH with very high specificity in baboon brain. The subject matter of the present disclosure did not reveal fixed reference regions without sEH binding in baboon brain, which is consistent with the widespread abundance of sEH in mammalian brain. (Sura et al., J. Histochem. Cytochem,, 2008; Marowsky et al., Neuroscience, 2009).

[0191] Analysis of radioactive metabolites in baboon plasma revealed 18 F-FNDP was demonstrated to be metabolized to two hydrophilic radioactive metabolites. By the end of the 90-minute PET scan, the remaining parent 18 F-FNDP exhibits ~20% radioactivity in plasma, which is comparable to many other PET radiotracers. Given the hydrophilic nature of the radiometabolites, they are unlikely to penetrate the brain to any appreciable extent, suggesting that kinetic modeling of the radiometabolites may not be necessary for quantification of sEH.

[0192] 18 We developed F-FNDP, the first specific PET radiotracer for sEH imaging. It is a potent sEH inhibitor. 18F-FNDP readily penetrated mouse (5% ID / g tissue) and baboon (SUV=4) brain and radiolabeled sEH with very high specificity (up to 95%) in both species while exhibiting reversible brain dynamics amenable to quantitative analysis. 18 The F-FNDP promises to enable further preclinical studies and human PET imaging to evaluate the role of sEH in various diseases and disorders, including VCI, mild cognitive impairment, and stroke.

[0193] [References] All publications, patent applications, patents, and other references mentioned in this specification are indicative of the level of ordinary skill in the art to which the subject matter of this disclosure pertains. All publications, patent applications, patents, and other references are incorporated herein by reference to the same extent as if each individual publication, patent application, patent, and other reference was specifically and individually indicated to be incorporated by reference. Although some patent applications, patents, and other references are mentioned in this specification, it will be understood that such reference is not an admission that any of these documents form part of the general knowledge in the art. In the event of a conflict of interest between this specification and any of the incorporated references, this specification (including any amendments thereto that may be based on the incorporated references) shall control. In this specification, unless otherwise indicated, the meanings of terms accepted in the standard art are used. Standard abbreviations for various terms are used in this specification.

[0194] Couto PJ, Millis RM. PET Imaging of Epigenetic Influences on Alzheimer's Disease. International journal of Alzheimer's disease. 2015;2015:575078; CNS Radiotracer Table (http: / / www.nimh.nih.gov / research-priorities / therapeutics / cns-radiotracer-table.shtml) 2015; Eldrup AB, Soleymanzadeh F, Taylor SJ, et al. Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009;52:5880-5895; Gao Y, Kuwabara H, Spivak CE, et al. Discovery of (-)-7-Methyl-2-exo-[3'-(6-[18F]fluoropyridin-2-yl)-5'-pyridinyl]-7-azabicyclo[2.2.1]heptane, a Radiolabeled Antagonist for Cerebral Nicotinic Acetylcholine Receptor (α4β2-nAChR) with Optimal Positron Emission Tomography Imaging Properties. J Med Chem. 2008;51:4751-4764; Heiss WD. PET imaging in ischemic cerebrovascular disease:current status and future directions. Neurosci Bull. 2014;30:713-732; Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol. 2000;27:627-630; Horti AG, Raymont V, Terry GE. PET imaging of endocannabinoid system. In:Dierckx R, Otte A, De Vries EF, Van Waarde A, eds. PET and SPECT of Neurobiological Systems. Berlin-Heidelberg:Springer; 2014:251-319; Hung YW, Hung SW, Wu YC, et al. Soluble epoxide hydrolase activity regulates inflammatory responses and seizure generation in two mouse models of temporal lobe epilepsy. Brain Behav Immun. 2015;43:118-129; Iliff JJ, Wang R, Zeldin DC, Alkayed NJ. Epoxyeicosanoids as mediators of neurogenic vasodilation in cerebral vessels. American journal of physiology Heart and circulatory physiology. 2009;296:H1352-1363; Iliff JJ, Alkayed NJ. Soluble Epoxide Hydrolase Inhibition:Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent. Future neurology. 2009;4:179-199; Imig JD, Zhao X, Zaharis CZ, et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension. 2005;46:975-981; Inceoglu B, Zolkowska D, Yoo HJ, et al. Epoxy fatty acids and inhibition of the soluble epoxide hydrolase selectively modulate GABA mediated neurotransmission to delay onset of seizures. PLoS One. 2013;8:e80922; Ingraham RH, Gless RD, Lo HY. Soluble epoxide hydrolase inhibitors and their potential for treatment of multiple pathologic conditions. Curr Med Chem. 2011;18:587-603; Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539; Knopman DS, Parisi JE, Boeve BF, et al. Vascular dementia in a population-based autopsy study. Arch Neurol. 2003;60:569-575; Lee CR, North KE, Bray MS, et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease:The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet. 2006;15:1640-1649; Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747; Marowsky A, Burgener J, Falck JR, Fritschy JM, Arand M. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism. Neuroscience. 2009;163:646-661; Martini RP, Ward J, Siler DA, et al. Genetic variation in soluble epoxide hydrolase:association with outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2014;121:1359-1366; Morris E, Chalkidou A, Hammers A, Peacock J, Summers J, Keevil S. Diagnostic accuracy of F amyloid PET tracers for the diagnosis of Alzheimer's disease:a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2015; Morris E, Chalkidou A, Hammers A, Peacock J, Summers J, Keevil S. Diagnostic accuracy of F amyloid PET tracers for the diagnosis of Alzheimer's disease:a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2015;43:374-385; Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases:their roles and interactions with lipid metabolism. Prog Lipid Res. 2005;44:1-51; Nelson JW, Young JM, Borkar RN, et al. Role of soluble epoxide hydrolase in age-related vascular cognitive decline. Prostaglandins Other Lipid Mediat. 2014;113-115:30-37; Qin X, Wu Q, Lin L, et al. Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism. Mol Neurobiol. 2015;52:187-195; Rohlfing T, Kroenke CD, Sullivan EV, et al. The INIA19 Template and NeuroMaps Atlas for Primate Brain Image Parcellation and Spatial Normalization. Frontiers in neuroinformatics. 2012;6:27; Shen HC, Hammock BD. Discovery of inhibitors of soluble epoxide hydrolase:a target with multiple potential therapeutic indications. J Med Chem. 2012;55:1789-1808; Shen HC. Soluble epoxide hydrolase inhibitors:a patent review. Expert Opin Ther Pat. 2010;20:941-956; Silbert LC, Dodge HH, Perkins LG, et al. Trajectory of white matter hyperintensity burden preceding mild cognitive impairment. Neurology. 2012;79:741-747; Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem. 2000;275:40504-40510; Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol. 2007;292:C996-1012; Sura P, Sura R, Enayetallah AE, Grant DF. Distribution and expression of soluble epoxide hydrolase in human brain. J Histochem Cytochem. 2008;56:551-559; Terashvili M, Tseng LF, Wu HE, et al. Antinociception produced by 14,15-epoxyeicosatrienoic acid is mediated by the activation of beta-endorphin and met-enkephalin in the rat ventrolateral periaqueductal gray. J Pharmacol Exp Ther. 2008;326:614-622; White L, Petrovitch H, Hardman J, et al. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann NY Acad Sci. 2002;977:9-23.

[0195] Although the foregoing subject matter has been described in some detail by way of illustration and example for purposes of clarity of understanding, those skilled in the art will understand that certain changes and modifications may be practiced within the scope of the appended claims.

Claims

1. Formula (I) 【Chemistry 1】 A compound of the formula: In the formula, X is 18 F. 76 B, 123 I, 124 I, 125 I, and 131 is selected from the group consisting of I; Y is -NR-C(=O)- or -C(=O)-NR-; m is an integer selected from the group consisting of 1, 2, 3, and 4; n is an integer selected from the group consisting of 1, 2, 3, 4, and 5; p is an integer selected from the group consisting of 1, 2, and 3; R is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted alkylheteroaryl, substituted or unsubstituted heteroalkylaryl, and substituted or unsubstituted naphthyl, substituted or unsubstituted biphenyl; Each R 1 are independently the same or different and are selected from the group consisting of hydrogen, halogen, alkoxyl, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted naphthyl, and substituted or unsubstituted biphenyl; and a stereoisomer or a pharma- ceutically acceptable salt thereof.

2. The X is 18 The compound of claim 1, wherein:

3. The compound of formula (I) 【Chemistry 2】 2. The compound of claim 1,

4. 1. A method of imaging soluble epoxide hydrolase (sEH), comprising contacting sEH with an effective amount of a compound of formula (I) comprising: 【Chemistry 3】 (Wherein: X is 18 F. 76 B, 123 I, 124 I, 125 I, and 131 is selected from the group consisting of I; Y is -NR-C(=O)- or -C(=O)-NR-; m is an integer selected from the group consisting of 1, 2, 3, and 4; n is an integer selected from the group consisting of 1, 2, 3, 4, and 5; p is an integer selected from the group consisting of 1, 2, and 3; R is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted alkylheteroaryl, substituted or unsubstituted heteroalkylaryl, and substituted or unsubstituted naphthyl, substituted or unsubstituted biphenyl; Each R 1 are independently the same or different and are selected from the group consisting of hydrogen, halogen, alkoxyl, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted naphthyl, and substituted or unsubstituted biphenyl; and a stereoisomer or a pharma- ceutically acceptable salt thereof.

5. The compound of formula (I) has the formula (II): 【Chemistry 4】 The method of claim 4, wherein the compound is

6. X is 18 F.

7. The compound of formula (I) is 【Chemistry 5】 The method of claim 4, wherein

8. The method of claim 4 , wherein the image is obtained using positron emission tomography.

9. The method of claim 4, wherein the compound of formula (I) is specific for sEH.

10. The method of claim 4, wherein the sEH is in vitro, in vivo, or ex vivo.

11. The method of claim 4, wherein sEH is present in a subject.

12. The method of claim 11 , wherein the subject is a human.

13. 12. The method of claim 11, wherein the compound of formula (I) is capable of crossing the blood-brain barrier and sEH is present in the brain of the subject.

14. The method of claim 11 which is non-invasive.

15. The method of claim 11 , wherein the compound of formula (I) enters the brain of the subject.

16. The method of claim 11, wherein the compound of formula (I) is excluded from the brain of the subject.

17. A pharmaceutical composition comprising a compound according to any one of claims 1 to 3 and a pharma- ceutically acceptable carrier, diluent, or excipient.

18. A kit comprising a packaged pharmaceutical composition comprising a compound according to any one of claims 1 to 3.

Citation Information

Patent Citations

  • Thienopyrroles as histone demethylase inhibitors

    EP2993175A1

  • Soluble epoxide hydrolase inhibitors and methods of use thereof

    JP2008540433A

  • HIV protease inhibitors

    JP2015527403A

  • Piperazine derivatives as HIV protease inhibitors

    WO2015017393A2